Epileptic encephalopathies encompass a heterogeneous group of epilepsy syndromes that manifest with cognitive, behavioral, and neurologic deficits, seizures that are often intractable and multiform, aggressive electroencephalographic paroxysmal activity, and sometimes early death. As more is learned about the etiologies and manifestations of epileptic encephalopathies, progress has been made toward better treatment options. However, there is still a great need for further randomized controlled trials and research to help create clinically effective therapies. The 2015 Neurobiology of Disease in Children symposium, held in conjunction with the 44th annual meeting of the Child Neurology Society, aimed to (1) describe the clinical concerns involving diagnosis and treatment, (2) review the current status of understanding in the pathogenesis of epileptic encephalopathy, (3) discuss clinical management and therapies for epileptic encephalopathy, and (4) define future directions of research. This article summarizes the presentations and includes an edited transcript of question-and-answer sessions.
was first described in 1841 by Dr West in reference to his own son. Typically, developmental regression is seen in conjunction with the occurrence of spasms.
Approximately 30% of all cases of epilepsy affecting infants are epileptic spasms. Spasms typically start between 6 weeks and 2 years of age, with the average age of onset at 6 months. A late-onset type of spasms occurs in children older than a year. These children will have a worse prognosis in terms of epilepsy and also in terms of development and may be on the spectrum with Lennox-Gastaut syndrome. The duration of spasms can last from 25 to 32 months. In 30% of patients, spasms stop spontaneously, especially in those who are under 7 years of age. Some case reports describe late-onset spasms lasting for 14 years. It is, therefore, the preferred International League against Epilepsy Terminology to use the term "epileptic spasms" rather than "infantile spasms," because epileptic spasms encompass the entire age group.
Dr Koh then reviewed electroencephalogram (EEG) findings in epileptic spasms. Interictally, they are often associated with hypsarrhythmia, which is noted mainly in non-REM sleep and is reduced in REM sleep. Hypsarrhythmia is a chaotic background with asynchronous large-amplitude slow waves of greater than 300 mV, and multifocal independent spike discharges mixed in between. Other EEG patterns may be seen as well, such as focal slowing, fast rhythms, and spikes and slow waves. In a third of patients, the EEG may be normal during the spasms and there may be a time lag in EEG findings.
Variations from the classic description of hypsarrhythmia are called modified hypsarrhythmia, and are without prognostic significance. Modified hypsarrhythmia may include focality, burst suppression, slow waves without spikes, and partial preservation of the background. If spasms persist, the background might become more synchronized and this might be indicative of Lennox-Gastaut syndrome. The spasms themselves may vary in EEG signature, including paroxysmal fast with attenuation, slow wave with electrodecremental response, general spike-slow wave, attenuation only, or generalized slow transient. Sometimes changes may be subtle and require video/camera to also time lock with viewing actual spasm to determine whether they are spasms or not. Pseudonormalization of the background can occur prior to or during the spasms as well. Hypsarrhythmia also might be seen in other conditions, such as nonconvulsive status epilepticus.
With regard to spasm etiology, an older classification scheme uses the definitions of symptomatic, cryptogenic, and idiopathic. Symptomatic means there is a known cause for spasms after the workup is done. Cryptogenic means spasms are thought to be related to a cause, but it is difficult to determine exactly what the cause is. (Many things are labeled cryptogenic but may be changed as a result of improved diagnostic techniques, especially in genetics and neuroimaging.) Idiopathic means spasms are not thought to be related to any cause, suggesting a more benign course or genetic etiology.
Currently, these definitions are not used by the International League Against Epilepsy because they are quite broad, and sometimes the connotation that idiopathic means a benign course does not hold true. In the International League Against Epilepsy classification, the etiologic categories are much more defined and include genetic, genetic-structural, structuralcongenital, structural-acquired, metabolic, immune, infectious, and unknown. The most common etiology is believed to be hypoxic-ischemic encephalopathy, found in about 10% of the population. Chromosomal abnormalities, especially trisomy 21, are found in about 8% of the population, as well as malformation of cortical development and perinatal stroke. Tuberous sclerosis is found in about 7% and periventricular leukomalacia or intraventricular hemorrhage in 5%. With the advent of epilepsy gene panels, numerous genetic mutations have been noticed in children who have epileptic spasms. However, these panels are very high in sensitivity and might be picking up some mutations that might not necessarily correlate precisely with the phenotype.
Spasms are frequently misdiagnosed by primary care physicians because they are very subtle and are not associated with a long loss of consciousness or generalized tonic-clonic events. Poor outcome is more related to a delay in diagnosis, regardless of the existence of congenital involvement prior to the start of the spasms. In a study conducted in 2012, 83 infants who had spasms were misdiagnosed, and researchers found that the majority did not receive a clear diagnosis from their primary care physicians. However, other misdiagnoses included gastroesophageal reflux, constipation, and colitis. Other diagnoses that can be mistaken for spasms include benign infantile myoclonus, shuddering attacks, spasmus nutans, and other types of seizures where there are myoclonic or atonic features, such as Dravet or Doose syndromes.
In a study from the United Kingdom Infantile Spasms Study (UKISS) group in 2005, researchers found that 61% of their patients had a known etiology found on evaluation, 33% had an unknown etiology, and 6% had an incomplete evaluation. More than half of the patients had etiologies that were diagnosed with magnetic resonance imaging (MRI) and physical examination. MRI provides better definition than computed tomographic (CT) scanning and is the modality of choice for neuroimaging. It should be repeated a second time when the child is older because myelination changes can occur in a young infant, and subtle cortical dysplasias might be picked up at an older age. If the MRI scan and the examination are negative, then genetic testing needs to be done, specifically with comparative genomic hybridization arrays, other epilepsy gene panels, or a mitochondrial panel. In addition, it might be helpful to complete a pyridoxine challenge because that may provide treatment. In a survey of other pediatric neurologists, only 42% of respondents regularly performed a pyridoxine challenge; 41% occasionally ordered it and 17% reported they never do it.
The mortality rate for spasms is about 12%, usually due to the underlying etiology causing the spasms. There is a spontaneous remission rate of 30%, mostly within the first 7 years of life. Factors associated with better prognosis for spasm control include cryptogenic etiologies, age of onset >4 months, if the patient had no seizures and a normal development prior to onset of spasms, and if there is no asymmetry noted on the EEG.
Other types of seizures occur in 50% to 70% of patients with spasms, predominantly temporal lobe epilepsy, especially in patients with tuberous sclerosis, who commonly have focal seizures after spasms have ceased or before spasms begin. Twenty percent to 50% of patients transition to LennoxGastaut syndrome. It is believed that perhaps spasms lie on one end of the spectrum and Lennox-Gastaut syndrome on the other, and that a gradual transition might occur, with tonic seizures happening as well as more synchronous discharges evident on EEG if the child's spasms persist.
Seventy to 80% of cryptogenic patients and 85% to 90% of symptomatic patients develop intellectual disability, which can depend on time to treatment. Hypsarrhythmia might be present prior to onset of clinical spasms, and might also be a cause of epileptic encephalopathy. Therefore, an important treatment goal is to resolve the hypsarrhythmia seen on the background EEG. Medications used for spasms can also add to epileptic encephalopathy.
Symptomatic etiologies prior to spasms are associated with worse prognosis for development and seizures than cryptogenic or idiopathic etiologies. Those with bilateral or diffuse brain lesions are also known to have a worse developmental outcome. The initial presentation of spasms with hypotonia or developmental delay more strongly predicts seizures and poor development. In addition, loss of visual tracking at the onset of the spasms might signify a worse prognosis. A study conducted in 2010 of 241 patients with infantile spasms revealed that 16 who had spasms thought to be idiopathic in origin all developed normally and their spasms resolved. Two later developed childhood absence seizures, which is a type of idiopathic epilepsy.
As previously mentioned, quicker treatment can result in better prognosis for development. This was seen in a study of 77 infants the UKISS group completed in 2011 that looked at time to treat and Vineland scores. The researchers found that prompt diagnosis and treatment help prevent developmental delay. Reducing total time of spasms (by decreasing the lead time to treatment and improving treatment response) helps with development. Younger infants were more at risk than older infants for epileptic encephalopathy, probably because of their brain immaturity. However, a study done in 2010 showed there was no association between the short lead time to diagnosis and developmental outcomes.
As far as current treatment for spasms is concerned, there is no clear consensus as to what treatment regimen is best. Seventy percent of providers are seeing fewer than 10 patients per year with new-onset spasms, which stresses the importance of having a consortium to identify treatment options. The aim of treatment is to stop clinical spasms and hypsarrhythmia, which in turn will help prevent future developmental regression. Most first-line medications, such as adrenocorticotropic hormone and vigabatrin, will stop spasms fairly quickly. Adrenocorticotropic hormone can stop spasms within a week and vigabatrin sometimes within a month. The relapse rate is about a quarter to a third of patients with spasms.
With regard to adrenocorticotropic hormone, a natural form (ACTHar) from a bovine source is used in the United States, and a synthetic form (tetracosactide) is used in Europe. The synthetic form has more side effects than the natural form because it is longer-acting; however, no study has compared these 2 forms. Also, there is no clear consensus whether low-or high-dose forms of adrenocorticotropic hormone work. High-dose adrenocorticotropic hormone is thought to be more effective, although it might be associated with increased side effects because it crosses the blood-brain barrier better than the low-dose form.
Oral prednisolone is also thought to help, but there is really no consensus as to whether adrenocorticotropic hormone or oral prednisolone is more effective. Several studies have looked at this, but have drawn different conclusions. The Pediatric Epilepsy Research Consortium protocol for adrenocorticotropic hormone is based on a study done by Baram in 1996 in which she looked at 29 infants randomly assigned to receive adrenocorticotropic hormone or prednisone. Of those treated with adrenocorticotropic hormone, 87% responded, compared with 29% who received prednisone. The protocol is a high dose of adrenocorticotropic hormone at 150 mg/m 2 divided twice a day for the first 2 weeks and then tapered quickly. However, adrenocorticotropic hormone is very expensive. Each vial costs $28,000. In addition, parents must be taught to administer it by intramuscular injection, and it is typically given in an inpatient setting because the child was just diagnosed with spasms through an EEG or MRI.
Steroids are associated with numerous side effects. Typically, providers also will give prophylactic antibiotics due to the immunosuppressive effects of steroids, as well as gastric acid suppressants because of associated gastrointestinal issues. Most physicians also request that patients see their primary care physician or a home health care nurse at least once or twice a week to monitor for blood pressure changes and for glucose in the urine.
Another option is vigabatrin, which typically stops spasms in the first 3 months of treatment. If no improvement is seen by 3 to 6 months, it is suggested the medication be stopped because of potential side effects. Higher doses are better than lower doses. In the 2005 UKISS study comparing steroids and vigabatrin, it was thought that steroids had better seizure control compared with vigabatrin at 2 weeks of treatment, but the effectiveness was the same after a year. Vigabatrin seems to be more effective than steroids in patients with tuberous sclerosis or cortical dysplasia.
Irritability, hypotonia, insomnia, and somnolence are the side effects most commonly seen. White matter T2 hyperintensities in the deep brain structures in corpus callosum are reversible and seen mostly in infants. However, visual field defects and direct optic nerve damage are irreversible and were seen in 34% of patients in one study. Side effects are usually associated with increased duration of treatment and possibly with concomitant anticonvulsant use. Taurine supplementation might be helpful in preventing visual field and direct optic nerve damage. The FDA requires that patients on vigabatrin be examined by an ophthalmologist every 3 months.
Second-line medications that may be used for spasms include felbamate, high-dose pyridoxine, valproic acid, clobazam or another benzodiazepine, zonisamide, rufinamide, topiramate, a ketogenic diet or low glycemic index, intravenous immunoglobulin, or epilepsy surgery.
Dr Koh concluded by providing current data collected by the Pediatric Epilepsy Research Consortium on spasms. The consortium of 38 pediatric epilepsy centers has enrolled about 230 patients with new-onset infantile spasms under the age of 2. The main goal is to identify numbers of children with the presenting information, etiologies, and short-term outcomes to provide baseline data for a larger comparative effectiveness trial. The etiologies found are similar to those identified by the UKISS group, in that about 64% of their patients did have a known etiology. The most common etiologies found were genetic or metabolic issues such as trisomy 21 and hypoxicischemic encephalopathy.
After 3 months of freedom from spasms, it seemed that the adrenocorticotropic hormone group had a much better response rate, especially compared with participants who received second-line medications, which were associated with a very low response rate. Those who had no developmental problems prior to spasms or those with mild developmental delay seemed to do better than those who had moderate or severe developmental delay prior to onset of spasms. In terms of etiology, those who had cryptogenic or unknown neurologic issues or etiologies with genetic or metabolic issues such as trisomy 21 did much better compared with those who had cortical dysplasia, who did not do as well. Those who had high-dose adrenocorticotropic hormone had a better response rate than those who had a low-dose form.
Lennox-Gastaut Syndrome
James W. Wheless, MD, University of Tennessee Health Science Center. Dr Wheless discussed Lennox-Gastaut syndrome. In 1939, Gibbs, Gibbs, and Lennox initially described the EEG finding of slow spike-and-wave pattern, which was later paired with the clinical findings of multiple seizure types by Lennox and Davis in 1950. In 1965 , the clinical features and EEG findings were put together by Dravet and later expanded on by Gastaut.
Lennox-Gastaut syndrome is typically diagnosed between the ages of 2 and 8 years, with peak onset between 3 and 5 years. Diagnosis in adolescents and adults is also possible. It is estimated to account for 1% to 10% of all childhood epilepsies, occurs predominately in males, and affects patients throughout their lives. The mortality rate is 3% to 7%.
The characteristic triad of clinical features includes multiple seizure types (mainly generalized), cognitive impairment/ developmental delay, and abnormal EEG findings of slow spike-wave discharges. Children might not initially display all of the characteristics and they may change over time. The multiple seizure types associated with Lennox-Gastaut syndrome are varied and include tonic, atypical absence, atonic, nonconvulsive status epilepticus, myoclonic, generalized tonicclonic, clonic, and partial. The hallmark seizure is the tonic seizure that occurs primarily in sleep.
Cognitive impairment in Lennox-Gastaut syndrome can range from mild to severe and continues to worsen over time. When Gastaut tested the IQ of 50 hospitalized children with the syndrome, he found that 80% had an IQ <50, half of whom had severe intellectual disability. Ten to 20% of patients with Lennox-Gastaut syndrome are within a normal range for cognitive function, but often have difficulties with daily tasks, with IQ seldom exceeding 90. Also, there is a progressive loss of intellectual functioning in many of these children over time. The hallmarks for the abnormal EEG findings are the slow-spike wave (1.5-2.5 Hz) and the paroxysmal fast activity of bilateral polyspike discharges during sleep without clinical features.
Lennox-Gastaut syndrome can arise as the result of multiple etiologies. Infantile spasms may account for 20% to 30% of cases. Overall, approximately 70% have a symptomatic etiology arising as a result of a brain injury or abnormality, with approximately 30% having a cryptogenic origin.
As with children who have infantile spasms, numerous genetic mutations have been associated with children who have Lennox-Gastaut syndrome. Some of those with genetic mutations have unique clinical features or imaging, but with others it is difficult to tell what the underlying genetic cause is based on phenotype. The Epilepsy Phenome/Genome Project is working to explore the genetic makeup of children with both infantile spasms and Lennox-Gastaut syndrome with no known cause and to further understand these genes to help with future treatment.
In the study, there were mostly males, all with epileptic encephalopathy of unknown cause. Ninety-three percent were diagnosed with Lennox-Gastaut syndrome within 1 year of seizure onset; 59% had normal development prior to seizure onset, with 11 patients having normal posterior rhythm on EEG. Only 11.8% had prior West syndrome. A detailed genetic analysis was performed, and it was found that de novo mutations were enriched in specific gene sets, including genes regulated by the fragile X protein. However, it was found that clinical phenotype could not predict a responsible gene. Because various genetic pathways resulted in epileptic encephalopathy, researchers explored the interrelationship between these mutations. They found that about three-fourths of the genetic defects in the cryptogenic group were associated with a protein involved in synaptic regulation, which will hopefully help to further progression of treatment methods.
First-line evaluation of Lennox-Gastaut syndrome, following clinical history and physical examination, includes brain MRI, EEG, and routine laboratory studies. If there are no abnormalities consistent with etiology, a chromosomal microarray may be done, which has a 12% to 13% yield. Urine organic acids, amino acids, and metabolic screening may yield an etiology in only about 1 in 50 to 100 patients. Targeted nextgeneration sequencing of epileptic encephalopathy panels has a high yield of about 12% to 13%. The Epilepsy Phenome/Genome Project is then suggesting whole exome sequencing be performed in those remaining.
Lennox-Gastaut syndrome may be caused by different structural, metabolic, or genetic abnormalities. This has led to the suggestion of a common neuronal network responsible for the clinical manifestations and EEG features of the syndrome. Simultaneous EEG and blood oxygen level-dependent functional MRI is a noninvasive technique that allows for evaluation of hemodynamic changes in the brain associated with interictal epileptiform discharges. In a study conducted in 2011, researchers found that during the slow spike wave, there was significant activation of the brainstem and thalamus. SPECT studies have also looked at this and found that the thalamus acts as a synchronizer and amplifier, and the pons appears to be involved in tonic seizures.
Dr Wheless then summarized studies from Archer (2014) and Blume (2001) that found that a common electroclinical phenotype, despite varying etiologies, suggests a common underlying mechanism. Functional neuroimaging confirms epileptiform discharges in Lennox-Gastaut syndrome recruit widespread areas of association cortex (diffuse association network activity) and spare primary cortical regions. Epileptiform discharges in Lennox-Gastaut syndrome are characterized by a breakdown in normal brain network behavior (coactivation of attention and default-mode networks).
With regard to the effect of Lennox-Gastaut syndrome later in life, at least 80% of these patients will have seizures that persist into adulthood. However, the features of the condition often change with age, and adult patients may display very different clinical and EEG features than they did in childhood. On EEG, the slow spike-wave is lost in about half of symptomatic cases with no known cause, and there is an increase in focal epileptiform discharges. Cognitive impairment worsens with age in most cases. Also, the number and variety of seizure types usually decrease, although tonic seizures tend to persist, particularly during sleep. In the past, Lennox-Gastaut syndrome was thought of as a uniquely pediatric epilepsy syndrome; however, with better care these patients are now surviving into adulthood.
Electrical Status Epilepticus in Sleep/Landau-Kleffner Syndrome
Edouard Hirsch, MD, University of Strasbourg. Dr Hirsch discussed electrical status epilepticus in sleep and Landau-Kleffner syndrome. He began by describing epileptic encephalopathy (as defined by the International League Against Epilepsy) as a condition in which the epileptic abnormalities themselves are believed to contribute to cognitive and behavioral impairment beyond what might be expected from underlying pathology. Electrical status epilepticus in sleep/Landau-Kleffner syndrome is defined as a self-limited childhood epilepsy with acquired alteration of cognitive and behavioral function with multifocal spike-and-wave, with a major activation during sleep. In all forms of electrical status epilepticus in sleep, there is disruption of cognitive function and mental impairment. Specifically, in Landau-Kleffner syndrome, there is a temporal predominance with severe deterioration of language. Treatments include benzodiazepines and ethosuximide as well as methylphenidate for behavioral disturbances.
Generally, epilepsies are classified by seizure type, including focal, generalized, generalized and focal, and unknown, with etiologies including genetic, structural, metabolic, immune, infectious, and unknown. In electrical status epilepticus in sleep, there are multiple factors such as interictal phases with transient cognitive impairment; sleep with consolidation of memory; synaptic molecular and cellular change induced by frequent seizures with bilateral network dysfunction; network maturation disturbance related to interictal spikes and waves with local overconnectivity and remote underconnectivity; genetic factors; lesions in the cortex and the thalamus; and default mode dysfunction with remote inhibition. Electrical status epilepticus in sleep can be separated into the developmental encephalopathy responsible for part of the cognitive impairment and related to genetic dysfunction in the lesions, and the epileptic encephalopathy related to classical focal seizures and spike-and wave-related syndromes.
Dr Hirsch reviewed previous studies of electrical status epilepticus in sleep, including studies of sleep homeostasis and genetic studies. It has been demonstrated that the role of sleep was disturbed, mostly in the down-scale of the slow activity usually observed during sleep related to spike-and-wave activity. In genetic studies, a relation between this group of diseases and autism has been shown. In a study conducted by Dr Hirsch and colleagues in 2010, 10% to 50% of these patients had a mutation of GRIN2A, which is related to cortical oscillation and maturation and can be attributed to acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction, as well as idiopathic focal epilepsy with rolandic spikes.
Additionally, there is also an immune system hypothesis associated with Landau-Kleffner syndrome etiology with autoantibodies as a cause or consequence of the condition. Lymphatic system dysfunction may be related to abnormality of the thalamocortical pathway with important activation during speech, and there might be specific immune activation in this situation.
With regard to treatment, studies have proven efficacy of benzodiazepines, steroids, and immunoglobulins. Use of personalized therapy with memantine in patients with GRIN2A mutation and early-onset epileptic encephalopathy has also been demonstrated and showed while there was no effect on the EEG, there was an effect on seizures. In a study by Downes and colleagues in 2015, subpial transections had no effect on patients with Landau-Kleffner syndrome.
Autoimmune Encephalopathies
Angela Vincent, PhD, Oxford University. Dr Vincent began her discussion on autoimmune encephalopathies with an overview of antibody-mediated diseases. In these diseases, antibodies bind to the extracellular domain of a protein that is an important protein usually on a membrane surface and involved in neuronal function. The antibodies can be measured easily in the serum and also in the cerebrospinal fluid. They tend to mainly cause loss of the target protein, or damage to the cell. Patients with these diseases can improve with immunotherapies, in particular plasma exchange, immunoglobulins, and steroids. Grey matter antibody diseases in children include voltagegated potassium channels-complex antibodies with autoimmune encephalitis, N-methyl-D-aspartate (NMDA) receptor antibody encephalitis, glycine receptor-antibody encephalomyelitis, and g-aminobutyric acid A (GABAA) receptorantibody encephalitis.
Acquired neuromyotonia, an autoimmune voltage-gated potassium channel disease mostly found in adults, is a spontaneous muscle disease caused by peripheral nerve hyperexcitability, with central nervous system involvement found in some patients. After antibodies to voltage-gated potassium channels were discovered in these patients, the condition was found to improve with plasma exchange or immunotherapies. These same antibodies were present in patients with a form of limbic encephalitis.
Previously, it was believed that limbic encephalitis was a paraneoplastic disorder, often of older people and generally very difficult to treat effectively because of the cancer and also because of the disease. However, patients with limbic encephalitis and voltage-gated channel antibodies are different. They tend to be nonparaneoplastic and tumors are uncommon. They have the same symptoms of seizures, cognitive dysfunction, and psychological disturbance, but MRI signs are restricted to the medial temporal lobes in many cases. They often have low levels of plasma sodium, and potassium channel antibodies are present in the serum, which usually are much greater in the cerebrospinal fluid.
These antibodies decreased with immunotherapies, with substantial clinical improvement. The antibodies in these patients are not usually against the potassium channels specifically. Rather, any antibodies can bind to any of the proteins in the voltage-gated potassium channel complex. The most important one, LGI1, one of the proteins of the complex, is associated with limbic encephalitis. LGI1 is mutated in autosomal dominant temporal lobe epilepsy with auditory hallucinations and is, therefore, a genetic target in some patients and an antibody target in others.
Faciobrachial dystonic seizures, very frequent brief dystonic events, often precede limbic encephalitis in some patients, and they are 90% associated with these antibodies, particularly specifically against LGI1. They are a very steroid-responsive seizure type, and often antiepileptic drug resistant. Interestingly, in these patients, there is not only limbic involvement but also basal ganglia involvement on positron emission tomography (PET), which raises the question of whether this is really an epilepsy or a movement disorder, or an overlap of the two. Unfortunately, in children, limbic encephalitis is relatively rare and the relationship to potassium channel complex antibodies is much less clear.
In children, high levels of voltage-gated potassium channelcomplex antibodies are more common in neuroinflammatory diseases than in noninflammatory diseases. They are not exclusively associated with autoimmune forms of encephalitis, and the targets of antibodies in those children are unclear. They are very seldom against LGI1 or CASPR2, which are the main 2 identified antigens in adults and may rather be binding to intracellular epitopes on this complex and therefore not pathogenic. Although they may not always be pathogenic, they may be a secondary biomarker of neuroinflammatory disease, and respond very well to treatment.
Dr Vincent then discussed NMDA receptor antibody encephalitis, which was originally described in young females with ovarian teratoma-associated encephalopathies but now is seen more commonly in patients without tumors as well. These patients often have prodromal fever and headache, usually leading up to a subacute presentation with neuropsychiatric features and seizures. This is then followed by movement disorders, autonomic dysfunction, and loss of consciousness. White cells in the cerebrospinal fluid are common, particularly at onset, and oligoclonal bands are seemingly rather rare at onset but may develop later. MRI findings are usually normal or unhelpful.
It is known that the antibodies bind to NMDA receptor antibody receptors and cause internalization. They also have caused loss of the NMDA receptor antibody receptor and cognitive defects in mice when injected into the ventricles, proving that these antibodies are almost certainly pathogenic. Antibody levels in the serum are always higher than in the cerebrospinal fluid. However, there are often high antibody levels in the cerebrospinal fluid, which is called intrathecal synthesis of that particular antibody. This raises the question of whether intrathecal synthesis is essential for central nervous system disease and if systemic antibodies from the serum that diffuse into the brain produce different clinical features than those produced intrathecally.
NMDA antibody receptor-mediated neurologic disease in children has become an important part of the spectrum of diseases that can be recognized and treated. In a surveillance study conducted in 2015 by Wright and colleagues, 66% only had first-line treatment, which included steroids and intravenous immunoglobulin, and 33% had second-line treatment with rituximab or cyclophosphamide. In these patients, there was a trend toward better outcomes in those who received plasma exchange as well as other treatments.
A recent study in 2014 by Hacochen and colleagues explored the clinical features of these patients. Twenty-eight of 46 (60%) patients had definite NMDA receptor antibody encephalitis, with all of the clinical features previously mentioned. Eight patients had atypical or partial phenotypes with just seizures and slight movement disorder or cognitive disturbance. Only 1 of these 8 patients was encephalopathic. Ten patients had white matter involvement and some of them had brainstem encephalitis, acute demyelinating syndromes, or post-herpes simplex virus encephalitis. A patient with herpes simplex virus encephalitis who initially tested negative for the NMDA receptor antibodies later developed these antibodies in the serum and cerebrospinal fluid, proving that the relapse was not a viral relapse but rather an antibody-mediated relapse. This further proved there is a widening spectrum of these NMDA receptor antibodies in adults and children, including the classic definition of NMDA receptor antibody encephalitis; partial phenotypes with predominant seizures, psychosis, and cognitive impairment; relapses after herpes simplex virus encephalitis; and those with white matter imaging changes. In all cases, prompt and effective treatment is required and effective. Many, although not all, make very good recoveries.
Glycine receptor antibodies, which have been described in adults, also were discussed. Glycine receptors are inhibitory receptors; therefore, if antibodies to them are present, the results include increased spinal and brainstem activity expressed as rigidity, spasms, sweating, stiffness, and autonomic disturbance. Some of these patients have tumors, mostly thymomas and lymphomas, and they are almost all responsive to treatment. These antibodies have also been identified in a few children and are precipitated by infections or stress, with good treatment responses. There are also GABAA receptor antibodies, mentioned recently by Joseph Dalmau and colleagues, which have been found to be present in children with severe forms of encephalitis who have seizures or refractory status epilepticus.
In recent studies, there were potassium channel complex, CASPR2, and NMDA receptor antibodies found in about 10% of patients with new-onset seizures but generally low levels. It was cautiously concluded that because antibodies are more frequent in pediatric patients with new-onset epilepsy of unknown cause, often with focal epilepsy features, this group might benefit from screening for antibodies in consideration of immunotherapies.
In conclusion, studies reveal that pediatric forms of autoimmune encephalitis are generally similar to those seen in adults. Encephalopathy, seizures, and cognitive and behavioral changes are common, and children are often apyrexic at presentation. They do not always have high cerebrospinal fluid cell counts, and not all of them have MRI abnormalities, making these features less helpful. They can be diagnosed by specific antibody, although lack of known antibody should not rule out a high suspicion of an autoimmune form and the appropriate treatment. Coexisting or previous infections are becoming quite common, and they do not rule out an autoimmune etiology for the patient's present symptoms. Also, some antibodies, such as the voltage-gated potassium channel-complex antibodies, are not always directly pathogenic and may be a biomarker for inflammatory, potentially treatable, disease.
Question-and-Answer Session. DR SHINNAR: So I would like to congratulate our speakers on not only giving informative and interesting presentations but on keeping their sessions on time, allowing us to actually have the full 20 minutes for questions. DR MARK KIDUR: I have a question about infantile spasms: When we talk about trying vitamin B 6 , what would be a reasonable approach? Because traditionally we say give them 100 mg once, and recently people are saying you might need to use the medication for 2 weeks, so if the kids are identified with spasm, you diagnose them, they are in the hospital, you give them one dose, and they do not respond, and you do not want to delay the ACTH or vigabatrin, how can we reconcile this? DR KOH: That is a very good question. It is a controversy as to whether to use 100 mg IV in the hospital or to send somebody out with 50 mg twice a day for 2 weeks. It has not really been worked out that I am aware of, and so it definitely is a conundrum like most infantile spasm evaluation and treatment, so it is not clear if that makes any sense.
DR. SHINNAR: If I may add, the Japanese literature has used B 6 frequently as chronic therapy. In the US, it has mostly been used as a challenge, there are no good RCTs [randomized controlled trials] either way.
AUDIENCE: With regard to the antibodies in the spinal fluid, what do we know about the perhaps background frequency of these in controls or in individuals who have had CNS [central nervous system] injury from other causes? Can these be an epi-phenomenon of brain injury, for example? DR VINCENT: Thank you for that question. I think it is a very important and interesting question, and one that I don't think has been properly addressed. There are quite a few studies now in adults looking at antibodies in serum from patients with a whole range of different disorders, and it does seem that sometimes patients develop antibodies to the NMDA receptors or potassium channels for reasons which may be completely indirect, but unfortunately we very seldom have CSF [cerebrospinal fluid] from those patients or from those individuals. As I showed you, the serum levels are usually higher than the CSF anyway, and if the serum levels are relatively low, this is going to mean that it is probably going to be quite difficult to identify the antibodies in the cerebrospinal fluid even if there are some there, and of course some does diffuse in, and so it is not an area that one can yet say anything about, but I agree it is important. DR INGRID LOMOMILLER: Is baseline neuropsychology testing important in the encephalopathies?
DR HIRSCH: If we are able to define what is baseline and what is latent period, then I think for the spectrum of ESES [electrical status epilepticus in slow-wave sleep] and atypical benign we start to have some criteria that we are able to recognize on EEG, criteria regarding which patient would be at risk or not; otherwise it is very expensive to do a deep neuropsychological in everybody, so I think even if this part is the benign part of the epileptic encephalopathy, in some of them maybe we should do and we start to have criteria depending on the EG aspect.
DR WHELESS: I would agree with that. The more atypical they get I guess the more we worry. The better they are doing in school, the less we worry, but even the typical-epilepsy isthe normal kids can still have school-related problems, so it does become a resource issue. Do we look at every single kid? Do we look at the ones in more detail that are having problems? I think the challenge is the resource. You can make an argument that they all would benefit to some degree, I think, but it really becomes a resource issue.
DR KOH: I definitely agree with what the 2 speakers have said, it would be lovely to have neuropsych testing. It is a little hard on our infants, but it would be lovely all the same. It is just a resource issue.
DR SHINNAR: If I may add-if you are going to do state of the art on clinical trials when you test drugs, then you do have the resources and cognition should certainly be part of it, which is different than-you can't always afford it in clinical practice. If a patient presents with psychosis, no fever, and acutely, a child, do you think of autoimmune and do they need a spinal fluid examination? DR VINCENT: I think it would be a very good thing if people did look at some of those children and adults who have a psychiatric presentation with some other evidence that there might be inflammatory disease, because the trouble is that we very seldom get spinal fluids from those patients and they are not usually considered, and the result is we don't know the answer whether in fact those are people who should be tested and who might benefit from immunotherapies rather than the typical drugs, but we are finding a few patients and some adult patients and in fact we have recently been involved in a case where the antibodies were very low at onset in the serum and rose over time, as the patient developed a more florid encephalopathic disease with the NMDA receptor antibodies, so it would have been much better to try to have caught the disease early in that case, and it wasn't done. They lingered in the psychiatric ward until later when they were moved to the neurological ward and treated. So I'm sure those cases exist in adults and I presume also possibly in children.
DR SAM CARR: At a recent meeting in Brussels, some data showed fairly convincing support for combined use of ACTH and vigabatrin, and I was beginning to wonder given our health care system and the cost consideration whether anybody sees this ever becoming a reality? DR SHINNAR: It is definitely an issue with our health care system, especially with the cost of ACTH and doing combined therapy, but it is definitely an interesting thought that maybe both medications used together will help those kids, especially with refractory spasms.
DR WHELESS: The other comment I might make is we certainly have plenty of other diseases where we have precedence to start with multiple therapies, whether it's hypertension, HIV would probably be the prototypical, and their therapies are not inexpensive or weren't, they have become less, and we start with multiple treatments. I think at the end of the day if we say there is a symptomatic group of kids with spasms, which we know respond less to whichever of the 2 treatments we pick poorly, if we can show that combining from the get-go in that group improves that outcome down the road, you become cost-effective to the system because these kids have a whole lifetime ahead of them, and 10 or 15 or 20 IQ points is incredibly expensive when you price it out over a lifetime.
DR SHINNAR: But to echo Jim's comment, those prototypes you mentioned, the use of multimodal therapy was supported by randomized clinical trials rather than by anecdote, so if ICISS generates such data I think the health care system will follow because these are bad and rare diseases. Just remember, the impact of 5 cents on a Lipitor tablet is much higher than whatever the cost of any of our drugs for a disease like infantile spasms due to its rarity, so it is really a question of demonstrating superior efficacy.
DR HIRSCH: Can I make a comment? The vigabatrin and ACTH is raising multiple factors-etiology and it is a question to Angela when I have a patient with-should I treat the symptoms with gammaglobulin or plasmapheresis or should I treat the etiology with steroids combining with gammaglobulin orand I just received mail asking me this question; should we combine steroids and gammaglobulin or should we start with gammaglobulin and do the steroids next? I would very much like to have the answer from Angela because I have to answer to my colleagues in France.
DR SHINNAR: We'll bring our demyelinating disease experts up to ask you the same question, right? DR VINCENT: Well, I would have to ask one of my pediatric neurology colleagues. I have one down there. I think with adults we always start with steroids, high-dose, well, IV preferably to start with, you know, it helps the blood-brain barrier seal up so it can't be bad, then high-dose steroids, and we don't wean them in adults until we really know there is some improvement. Now, I know in children everybody feels much more cautious and understandably, and IVIG sometimes is sufficient, but I think at least perhaps some IV methylprednisone every now and then to sort of help it along. DR HERB GILMORE: I'm struck by the common theme across all of the talks of encephalopathy, and I'm wondering if we can come up with a better definition. I think Dr Hirsch was alluding to this. How do we define encephalopathy? And I think therein is one of the problems of trying to differentiate the patients that were questioned whether they have a psychosis. To me having a psychosis does not mean that you have an encephalopathy, so I'm just wondering if we can have a better definition of what that actually is.
DR HIRSCH: I think we mentioned it is important what we are speaking about, encephalopathy there is a definition, something in the brain, and psychosis it is a form of encephalopathy, so I think it is in the brain not in the liver as far as I understand, and so after what is epileptic encephalopathy and immune encephalopathy we have to accept there are different factors, and that is what we will-for the next generation. If we focus on one factor, we simplify and now we can go to the complexity.
DR SHINNAR: Partly the common theme was our fault, Tallie, and mine, because we selected the topics to present, syndromes associated not just with seizures but with encephalopathy, however broadly defined it may be that in some cases seizures are refractory and in others less so, but that being their shared component, and I think that was our fault for selecting the syndromes precisely to reflect that.
DR VINCENT: Let me just add a quick comment. I think it is a very interesting question, and perhaps a way to answer the questions in encephalopathy is to go deep into the brain and understand what in the brain causes a nonencephalopathic behavior and encephalopathic behavior, and we will be doing that in the neurobiology session that comes next, so just hang in after the coffee.
DR JOHNSON: A question about Landau-Kleffner syndrome. I trained with Dr Landau and I've known this syndrome for a long time and have always found it be very perplexing and difficult. Most recently a patient with fluctuating auditory problems or encephalopathy if you will without much in the way of seizures and with oligoclonal bands in the spinal fluid. I have been impressed with the lack of cohesion among child neurologists or epileptologists about looking at the autoimmune aspect of this particular disorder, and I wonder if all of the panelists could comment on their experience with that or their suggestions how we might approach that problem.
DR HIRSCH: Angela raised the question to define focal epilepsy of unknown etiology, so wherein we have a child with focal epilepsy, unknown etiology, an acute one, what should we do-very fast, immune screening, or should we do a lumbar puncture looking about intrathecal oligoclonal bands, so we have to define for the population enough that we define a protocol and do it in the right way in a collaborative way because it is-disease, but we have to-the way. I don't think there is-DR VINCENT:
[interposing] I think, if I may, that when you have a new entity that you want to really define as immunemediated, you need very good clinical data, you need proper collections of serum and CSF, preferably you also need some tissue to see if there is some IgG bound there. I mean that is all very difficult, and the fact is that most of the studies done in these sorts of situations are on individual small series of patients, the clinical data is not always very good. The samples are not always very good, and the assays done are often not the most appropriate. You need to look for binding to the tissue and you need to look for binding to extracellular epitopes on thethat would be important in that target tissue, and that doesn't happen very much. Joseph-has really established a very nice approach for looking for new antibodies, which has been very fruitful, and that is the sort of approach, tissue, cells, good samples, and good clinical data that you need.
AUDIENCE: A quick comment to follow what Stan Johnson asked Edouard. Before Edouard published that first paper with 3 patients with steroids, a long time ago there was one isolated report from Spain that described a small series of children with Landau-Kleffner. They apparently demonstrated vasculitis by doing-actually angiogram, and I remember being puzzled because that is considered pretty invasive, we wouldn't have done that in the States, but that is the only report that I know and as you know, that paper did not have any images.
Molecular Features and Pathogenesis
Vulnerability of the Developing CNS Gregory Holmes, MD, University of Vermont School of Medicine. Dr Holmes's discussion covered the vulnerability of the developing brain and the comorbidities of epilepsy, mainly focusing on cognitive impairment. In Lennox-Gastaut syndrome, for example, more than 90% of these patients have an IQ below 60, and cognitive impairment is often used to define the condition. This raises the question of whether it is the etiology of LennoxGastaut syndrome that leads to the cognitive problems or the seizures or the EEG abnormalities themselves causing these problems. There are some indications, however, that some of these children improve with epilepsy surgery. Dr Holmes discussed a study looking at 42 children with Lennox-Gastaut syndrome whose IQs were quite low but improved in some who had a postoperative decrease in seizures. Similarly, studies comparing children with infantile spasms of cryptogenic versus symptomatic etiology did not make much difference in their degree of mental retardation. Another study, done in the United Kingdom, looked at the IQ of children with tuberous sclerosis, both with infantile spasms and with other types of seizures. They found there was a dramatic decrease in IQ in patients after the onset of infantile spasms. In patients with other types of seizures, there was no change. They looked over time at the children who had infantile spasms, assessing how long these children had infantile spasms, and found there was a decrease in IQ over time if the spasms continued.
In Dr Holmes' laboratory, researchers have been working to break down the epileptic encephalopathies by looking at the core features, seizures, and EEG abnormalities. They use normal rats, which eliminates the variation of different etiologies. They are inducing seizures using inhaled flurothyl, which causes them to have generalized tonic-clonic seizures, about 7 to 10 per day. They then test them with a variety of cognitive tests.
In another group of rats, febrile status epilepticus is induced for 30 minutes or more. They then perform the Morris water maze. This is done by dropping a rat into a tank of water with some cues around the tank and a platform in the middle of the tank or in one quadrant of the tank submerged in water. The rat will find this by accident initially, but if the cues are kept the same, it will eventually swim directly to the platform, using visuospatial cognition to find it.
In rats with induced seizures, researchers look at the latency, how long it takes for them to find the platform, 6 trials per day for 4 days. They found that rats that had seizures early in life had a great deal of difficulty finding the platform. They eventually find it, but they never quite reach the level of the control animals, proving they have cognitive difficulties. Interestingly, there is no cell loss when looking at the brains of these animals.
From a physiologic standpoint, they also look at single-cell action potentials, using tetrodes placed in the hippocampus, typically the CA1 region, and record action potentials from single cells. A light source is placed on the rat's head and while the rat is running around, its position and action potentials are recorded. While the rat is put in a cylinder with a cue card and running around, there are action potentials occurring in certain locations of the arena it is in. There are also intraneurons that fire much quicker and do not have any particular field or place localization. These are called place cells, and are very specific for the animal's location in space. The place cells fire when the animal is running around in space and also when the animal stops running or is asleep. When the animal is asleep, researchers replay or reactivate the cells that occurred when it was running, so this is a reactivation of these place cells that are firing, and it appears that this may be one of the mechanisms for memory and consolidation of memory during sleep.
When the place cells fire, called rate coding, they fire based on a certain location. There is also a relationship between how cells fire and the rhythms of the brain. In rats, an important rhythm is the theta rhythm, and when the animal is engaged in a task, the theta activity occurs when the animal is actively moving. During a task, there is a band of theta activity that occurs in the time that the animal has to make a decision as far as getting the task correct. Place cells fire in relationship to theta, so, for example, when the animal is running through a field, the action potentials occur earlier and earlier about the theta wave, and this is called phase procession. If you have a couple of cells that have an overlapping field, there is a mechanism with phase process that is called theta time between these action potentials that corresponds with distance. Timing of the action potential is dependent upon theta activity, and this is called temporal coding, emphasizing that rhythms of the brain are extremely important for cognition.
One of the tasks used is to put a demand on the animal while recording single cells. An active avoidance test is performed, wherein there is a rotating arena, and a shock zone. After training the animal, it learns to avoid the shock zone. When it gets close to the shock zone, it will turn around and go the other way. It has already learned the task, and it is therefore a test of medulla, because there is a little bit of fear conditioning, but mostly of spatial cognition, because it has to learn the cues and figure out where the shock zone is. Rats that had induced febrile status epilepticus that underwent the active avoidance test did not go into the shock zone; however, their strategy was different. An important lesson to be learned from this was that just because an animal does not have any deficits following status epilepticus doesn't mean that brain did not change.
Researchers also looked at the stability of the place cells. Both the febrile seizure learners and the nonlearners had less stable fields than the control animals, proving that the febrile seizure learners are not spared from injury. Additionally, they looked at the field size to get an idea of how precise the firing patterns are in the cells. Animals that were febrile seizure learners were in a field firing radius similar to controls, but the nonlearners' field size was quite high. This is again another indication from a physiological standpoint that animals that have had status epilepticus as baby rats learn in a different strategy. Lastly, when the animals were placed in the active avoidance test, which depends on memory, both the controls and the febrile seizure learners switched their phase of CA1 neurons to the theta to fire at the peak of theta. Again, when firing at the peak of theta, this is the best way for learning to occur. Entorhinal cortex fibers come into the CA1, and this is the most likely time to get a long-term potentiation at this particular firing pattern.
Dr Holmes then discussed coherence. Coherence is the amount of signal given at a certain frequency. When looking at action potentials in different regions of the brain-for example, the hippocampus and the prefrontal cortex-if there is poor coherence, the action potentials are not well-synched together between the 2 structures. If the coherence is improved between the hippocampal theta and the prefrontal theta, when looking at the action potentials, there is a high degree of synchronous firing, and, therefore, coherence will help determine how individual cells in the hippocampus and the prefrontal cortex work together and fire together. This is important for memory consolidation and information processing.
In the laboratory, coherences of rats that had 100 flurothylinduced seizures were studied. Researchers compared rats that had early-life seizures with controls, and found in tasks that required memory, learning was delayed in rats that had seizures. However, with overtraining, they interestingly advance just as well as the control rats. With regard to coherence between the 2 structures, they looked at both gamma and theta between the prefrontal cortex and the hippocampus and found that animals with early-life seizures that eventually learn to get the task had increased coherences between the hippocampus and the prefrontal cortex, and they were running much higher coherences than the control animals. The animals that were able to increase their coherence would consistently get the task right and those that had seizures that did not increase the coherences did not get the task right.
Oscillations are important for cognition, and with regard to therapeutic treatments, there is a question of whether oscillatory activity can be ordered. Using channelrhodopsin followed by light stimulation, channelrhodopsin can be injected and oscillatory activity can be controlled. In Dr Holmes's laboratory, researchers injected channelrhodopsin in the medial septum and were able to control hippocampal oscillations with this optic stimulation, which covered EG and oscillatory activity. With regard to interictal spikes, another study was done by Dr Holmes with rats with a history of pilocarpine-induced status epilepticus. Some would have spikes during the training and others would not. Those that had spikes during the training had a markedly decreased ability to retrieve information.
Researchers also put induced interictal spikes in the prefrontal cortex, and these rats did not have seizures but had increased plasticity in the prefrontal cortex and also a lot of admissions. The rats were inattentive when performing the tasks, and thus these interictal spikes in themselves led to cognitive impairment. When evaluating children, previous studies have shown that during single spikes, there is transitory cognitive impairment. This raises the question of what happens during electrical status epilepticus in sleep when there are numerous spikes.
Dr Holmes concluded with a discussion of Dravet syndrome, wherein children have many seizures and ataxia, and the majority of them experience intellectual decline over time. In his laboratory, they have tried to mimic the knockdown of sodium 1.1 in the medial septum of rats, which sends fibers to the hippocampus, which will control theta activity, and these are mainly in fast-spiking interneurons. They are able to knock off the theta in the hippocampus. These rats do not have seizures, so they have the underlying genetic abnormality but they do not have any spontaneous seizures. When tested in a spatial cognition test, the controls did better, thus proving that etiology plays an important role in cognitive function in addition to the EEG and interictal spikes.
Neuroinflammation
Sookyong Koh, MD, PhD, Emory University. Dr Koh discussed neuroinflammation and the role of anti-inflammatory agents in reducing seizure susceptibility. For some time, there has been a suspicion that the immune system can affect the evolution of intractability in epilepsy. Immune cells have been detected in the brains of patients with refractory epilepsy and steroids have been used as anti-inflammatory treatment, with a subsequent anticonvulsant effect. This has especially been found in certain drug-resistant forms of epilepsy, such as adrenocorticotropic hormone and prednisolone in infantile spasms, Landau-Kleffner syndrome, and, occasionally, drug-resistant myoclonic atonic epilepsy. Febrile seizures, one of the most common seizures that affects up to 8% of children across the world, occurs in the setting of infection or inflammation, and the role of cytokine as a cause of febrile seizures has been pretty well established. There is also a high incidence of seizures in systemic autoimmune disease such as multiple sclerosis and systemic lupus erythematosus. Rasmussen encephalitis has been appreciated as immune-based.
The microglia is the only antigen-presenting cell in the innate immunity of the central nervous system. Microglia are rapidly activated whenever there is a brain injury or any kind of insult. Dr Koh has been looking at the role of activating microglia in the pathogenesis of acquired epilepsies. The study of microglia has been enhanced and helped by the use of this chemokine receptor GFP/þ mouse, which can be visualized and quantified, with focus at the activation. In the first 2 weeks of life in a rodent, which equates to early childhood and infancy, there are increased numbers and fluorescence of microglia within the hippocampus. This peak of microglia proliferation coincides with explosive synaptogenesis, and this coincides with increased susceptibility to any trigger, such as hypoxia or fever. There is a temporal susceptibility that coincides with the developmental upregulation of microglia, during which microglia are activated and transiently increased.
In Dr Koh's studies, a model was created based on the hypothesis that animals exposed to seizures early in life that were then challenged again in later life had greater neuronal injury. There was an exaggerated response to the second seizure by the microglia, which raised the question of whether an anti-inflammatory agent can be used to inhibit microreactivation and block the epileptogenic effect of early-life seizures. Numerous drugs were tested and the rats were challenged 2 weeks later, after microglia activation had gone down. Approximately half the animals died. However, those given 7 days of minocycline had improved survival. About 75% of those that received dexamethasone for 5 to 7 days died, and those that survived had failure to thrive. Researchers attempted to give dexamethasone for 2 days and found that after the first hit, in the second hit there is an exaggerated microglial activation along with cell death, which could be reversed by posttreatment with dexamethasone. When studying mice, they found that a second hit increased both seizure susceptibility and increased microactivation, and when using minocycline for 7 days, there was a decrease in microglial activation, and susceptibility and microactivation were reversed.
When looking at the different kinds of gene expression in a blinded analysis, of the 253 "seizure-specific" genes detected, two-thirds of them were upregulated and one-third were downregulated; in the immature brain, they were all normalized. This proved there is an increased innate ability to heal itself. Seizures caused 2503 genes to be up-and downregulated. However, they were able to normalize within 3 days. A single seizure in the immature brain can be recovered from quite well. However, multiple seizures, without time to recover, may be more detrimental.
In a study conducted by Dr Koh, rats were housed together for about 10 days, as opposed to living in isolation. Researchers found it was hard to distinguish those that had seizures from those that did not. Koh found that those housed together had a quick response to a second seizure, whereas those housed alone had a severely lowered seizure threshold. The effect was completely reversed if they were in an enriched environment for 10 days after status epilepticus. Additionally, they saw high upregulation of inflammation-related genes, which then normalized. Those housed in isolation never recovered and had persistence of the activated microglia, whereas in those in an enriched environment, the activated microglia were completely gone. This stressed the importance of providing an enriched environment to children following seizures.
Independent of etiology, there was innate immunity activation, and subsequent cell death. This raises the question of the progressive nature of uncontrolled seizures in patients who undergo surgery years later and experience progressive loss of IQ as a result of widespread cell death. In addition to microglia activation, in the epileptogenic zone, there is a large number of cells present, including the absolute number of CD4-positive and CD8-positive cytotoxic T cells. The ratio of CD4-positive and CD8-positive cytotoxic T cells in the brain of epileptic tissue is reversed from what is seen in the blood, with an increased number of cytotoxic T cells in the brain. Surprisingly, activated microglia were not found to correlate with seizure frequency, but rather, were correlated with professional antigen-presenting cells.
The idea is microglia are activated, innate immunity and then innate antigen-presenting cells come in, which then signal T cells to enter. When studying these patients, it was found that those who had the greatest number of infiltration of antigenpresenting cells included those with Rasmussen encephalitis, known as a prototype of immune epilepsy. There were also high numbers in encephalomalacia and lower numbers in medial temporal lobe epilepsy. In those with Lennox-Gastaut syndrome, who have multiple type of seizures in high frequency, CD3-positive T cells in the brain are comparable to the number seen in Rasmussen encephalitis. Also, another subgroup with high antigen-presenting cells and CD3-positive T cells were those with epileptic spasms.
Additionally, gamma delta T cells were also detected in the brains of patients and mice with recurrent seizures. Compared to blood, the percentage of gamma delta T cells in the brain was much higher of the total CD3-positive T cells, up to 70% of CD3-positive T cells in the brain. The importance of this is that the gamma delta T cells are implicated in epitope spreading and autoimmunity in multiple sclerosis.
In a study by Matthem and colleagues on Rasmussen encephalitis, involvement of gamma delta T cells were found; it is also seen in focal cortical dysplasia and encephalomalacia, especially if they had very frequent seizures. Also, in a study by Vezzani and colleagues, the blood-brain barrier and its contribution to pharmacoresistant seizures were examined. They found that bloodborne immune cells are not needed to sustain seizure recurrence. Rather, blood-brain barrier damage might be the initiating event. The innate immunity and microglial activation might be the initiating event, which then leads to blood-brain barrier dysfunction, which then leads to infiltration of peripheral immune cells that exacerbates the whole process.
In conclusion, there is a nonlinear, amplifying feedback loop of crosstalk between innate and adaptive immunity. The microglial activation leads to infiltration of professional antigen-presenting cells, which then cause T cell infiltration. Some of the T cells, gamma delta T cells, function as both innate and adaptive immunity, and thus neuroinflammation predisposes, precipitates, and perpetuates epileptogenesis.
How Does Pathogenesis Guide Therapeutic Strategy?
Tallie Baram, MD, PhD, University of California Irvine. Dr Baram focused her discussion on the pathogenesis of epileptic encephalopathy and how understanding this can help to guide treatment. In the case of West syndrome or infantile spasms, there are hundreds of etiologies. However, in the case of Dravet syndrome, there is a similar phenotype, seizures, cognitive problems, and decline. It is known that the insult is a mutation at an ion channel, but how does this mutation lead to epileptic encephalopathy? Also, do seizures lead to the cognitive deficit or are there 2 separate entities that influence one another?
When the effect of the sodium channel mutation on cognitive deficit and seizures was isolated, it was found that it is not only the seizures that cause cognitive problems. Both cognitive deficits and seizures are a consequence of network disorder. Fundamentally, the properties of the network relate to the properties of the neurons involved, and if not functioning properly lead to seizures and cognitive impairment. The functionality of the neurons depends on the genes expressed. This raises the question of how mutations in single genes can lead to epileptic encephalopathy. There are the neuronal effects, including the direct effect on neuronal function, dysfunction of neurons causing them to die, circuit reorganization, and neuronal injury triggering large-scale epigenetic mechanisms. If dysfunction of the neuron kills them and there is circuit reorganization, new abnormal synapses will form and an abnormal network results.
When looking at the MRI or postmortem in the brains of most children with genetic problems, there are no overt abnormalities seen. However, abnormalities can be seen in mouse models. For example, in the case of the stargazer mutation, which causes absence seizures, the thalamus and cortex are abnormal and produce the equivalent of a 3-second spike wave. When looking at the hippocampus, there are more new and excitatory synapses consistent with an abnormal network in the face of a genetic mutation that doesn't seem to have anything to do with the hippocampus. The idea is that one of the ways in which an insult, even a genetic insult, will cause encephalopathy is by causing secondary changes independent of the focused nature of the mutation by injuring neurons and sometimes by killing local ones. Therefore, in addition to potentially having a direct effect on neurons or causing dysfunction or death of neurons and circuit reorganization, insults, whether genetic or acquired, can change the properties of a neuron into an epileptic one. Consequently, if able to reverse the repression of the affected genes to prevent downregulation, it is possible to attenuate the epilepsy. Additionally, there is a change in human tissue taken from epileptic patients that might be quite important.
A commonality between acquired and genetic causes of epileptic encephalopathy is that both interact at the level of the epigenome; both cause aberrant expression of genes either because these genes are mutated, don't function correctly, and have downstream effects on others, or because there is a change to the environment through insults such as fever, infection, or stress, which influences genome-encoded gene expression and ultimately dictates phenotype. Epigenetic processes govern the function of the genome. For example, through the processes of methylation and demethylation, DNA and histones are chemically altered to express or not express genes. When there is an insult, whether a genetic mutation or an acquired insult, it alters supply and demand in a cell. In the context of epileptic encephalopathy, many seizures occur that use excessive energy, or there is a stroke or dysplasia that limits blood supply and nutrients to the cell. This leads to the signal altering the metabolic balance in the cell that directly activates an enzyme that acts on the chromatin and influences gene expression. These enzymes are sensitive to the metabolic state of the cell. Several kinds of insults will coalesce on a common mechanism of altering gene expression, affecting aberrant gene expression, micro-RNA, and noncoding RNA. These epigenetic mechanisms might provide targets for intervention in the development of the epileptic encephalopathies of diverse origins.
In addition to neuronal effects leading to epileptic encephalopathy, there are nonneuronal effects, including inflammatory activation as a result of neuronal death or injury and deficits in helpful glial functions, including both synaptic and metabolic functions. With regard to inflammatory activation, following an insult to the neuron, metabolic sensors on the neuron activate the chromatin. The neuron also has cell stress and cell injury sensors. One of them is a molecule called highmobility group B1 (HMGB1). This molecule, located in the nucleus, contributes to overall structure. With neuronal stress, HMGB1 gets dislocated to the cytoplasm, exits the neuron, and binds to receptors on inflammatory factors, activating an inflammatory cascade.
This inflammation may contribute to the epileptic encephalopathies via numerous pathways. One such pathway is the activation of glia and neurons, causing the release of cytokines, activating astrocytes, and triggering glutamate release. Astrocytes strongly influence synaptic function via control of glutamate levels, extracellular space volume, synaptic dimensions, and pH. They play a role in altering the functionality of these synapses, which generate oscillations in learning and memory. During development, astrocytes modulate the number and maturation of synapses. Glia and neurons interact closely to regulate neuronal metabolism, which influences the normal functions of neurons and neuronal networks. It is therefore crucial to not only focus on neurons when approaching therapeutic interventions of epileptic encephalopathy but also on nonneuronal components of brain networks.
To summarize, insults can be genetic, acquired, or both, and they have secondary results on neurons, including killing them or impairing synaptic plasticity, which will influence the neuronal network. Many different kinds of insults also change the property of neurons through large-scale epigenetic changes, and these persist. These may be associated with altered metabolism, ongoing seizures, or neurons functioning inefficiently because channels or other molecules are wrong, and this will create an augmented demand without sufficient supply. Additionally, there also may be changes in the glia that influence neurons in many different ways through metabolism, through inflammation, and through impaired synaptic function. All these together coalesce to result in abnormal function of neuronal networks, manifesting as ongoing seizures that have their own side effects as well as cognitive problems, and this results in the 2 hallmarks of epileptic encephalopathy.
This framework suggests several potential areas for intervention. There are drugs that can selectively influence epigenetic changes as well as drugs that can influence inflammation, and drugs that can influence metabolism. In a given patient or in a given syndrome, these processes will have relatively altered importance, and their respective contribution will vary. It is therefore important to understand the epileptic encephalopathy syndrome in terms of the relevant or respective or relative contribution of genetic or the acquired, and of epigenetic versus inflammation, in order to tailor it using a cocktail of interventions to alter the course of a given epileptic encephalopathy syndrome.
Question-and-Answer Session. DR HIRSCH: Could antiepileptic drugs be aggravating inflammation or worsening things? DR BARAM: OK, if I understood the question, do our antiepileptic, anticonvulsant, or antiseizure drugs have, in addition to controlling seizures, other properties that influence other processes? The answer is absolutely yes. I do not think we can use a sledgehammer. For example, if we were to interfere with epigenetic processes, I don't think stopping all methylation would be the case. Yes, when we give antiepileptic drugs or anticonvulsants, we are modifying all kinds of things that we don't know. Sometimes we know because of allergies and reactions, we modify the kidney, we modify the liver, there is no doubt that-acid has an effect that is, you know, involves metabolism, that involves inflammation and some epigenetic processes. Absolutely, we do not have the magic bullet or the silver bullet, and it's a very important question that you raise Edouard.
DR PHILIP PEARL: This is a question for Dr Koh. So child neurologists have observed for years that steroids can be very effective in a child with insipient Lennox-Gastaut; it's more or less anecdotally that you could almost support the whole evolution of the epilepsy and the epileptic encephalopathy with steroids. Based on all of the fantastic research you presented, can you support that practice, and have we learned enough about the inflammation to guide how this may or may not be best approached, bolus, long-term, approaches to antiinflammatory in this situation?
DR KOH: Thank you so much for your comment and suggestion. I was very surprised to see really the infiltration of the immune cells from the periphery in the Lennox-Gastaut syndrome, for the epileptic surgery specimen was not meant to inform the medical treatment in a way. The answer for this child was surgery, and so we are learning for those who are surgical candidates and steroid long-term is not going to be the answer. I think we might have to learn more; we are beginning to learn more from the epileptic specimens that not all inflammatory and immune cells are bad, and we need to tailor it. It would be very difficult for anyone to say, well, use steroid all the time, but we have experienced ourselves and our teachers have used steroids, pulse steroids to help encephalopathies, I agree.
DR BARAM: I'd like to make a comment. One very surprising, and intriguing, and alarming finding by Sooky was the death caused by steroids in immature rats. In this particular case, rats are rats and humans are humans, and I think Sooky and I discussed that. When you give steroids to a baby rat but not a baby human you shut off the-corticoids in the adrenal anyway and yes, if you do that beyond the, below the agecorticoids begin, you are going to kill the rat. This does not happen in humans, where the mineralocorticoid function is independent of dexamethasone already at birth, so I think that particular point needs to be very well clarified, that some of the hazard of using steroids in-rats, do not apply to humans. DR NEAL KAMIL: I'm very pleased to hear all of the discussions regarding the effects of the inflammatory process that goes on with encephalopathy. You have also touched on autism and other cognitive functions, so my question is actually about can we expand this concept of having these problems leading on to not only autism, ADHD, and other problems, which are-lasting problems for children who may have gone through encephalopathy, and does anti-inflammatory have any role in preventing or recovery from ADHD? DR KOH: But whether inflammation is involved in our understanding of autistic spectrum behavior, I think we are beginning to appreciate it more and more, yes, there is synapse elimination, there is network dysfunction, and inflammation seems to be involved in autism as well as epilepsy. I agree.
DR KAMIL: Thank you.
MODERATOR: I would just throw in a comment. I think this is where your evidence about environmental enrichment both improving outcomes and reducing inflammation is very exciting, and I know that Dr Holmes also has some evidence about improvement in cognitive function in a variety of factors with environmental enrichment. So I mean that would certainly be, that doesn't carry the same risks as a lot of our antiinflammatories, so again I think encouraging a very positive environment to the degree that we can in therapies and good school environments would you know, is an easy way to at least begin to address that question with little potential for adverse effects.
DR KOH: Just to add to Dr Baram's explanation of epigenetic mechanism, how it could cause epilepsy, the environmental enrichment appears to be working with epigenetic mechanism as far as we understand it. Love them I suppose.
AUDIENCE: That is what my question was, is this is a very important observation that environment enrichment helps maybe prevent further seizures; this may apply to other paroxysmal events, such as headaches, and syncope and so forth, where lots of the functional disorders that we see where we know that quick return to school and function is very helpful, and in disorders of anxiety, etc., that have been shown to show long-term effects, adverse effects in adults, like anxiety in childhood, etc., so the mechanism is purely epigenetics, is that something that we have studied or is that theory or some kind of poor coping that alters the cognitive and autonomic, etc., centers?
DR KOH: Best evidence for the role of epigenetic mechanism in environment enrichment was done in our animal model of Alzheimer's disease; there they were able to show retardation of dementia or worsening of cognitive dysfunction in an animal model of Alzheimer's disease and they show changes in epigenetic mechanism, but I do believe that is how it probably works, and I appreciate your broadening, generalizing this benefit to other neurologic disorders.
AUDIENCE: It highlights how important is the initial treatment and management of these patients including the first seizure, the reassurance, the return to school, counseling, education, and I think that is so important in these other conditions as well. Thank you so much.
DR VINCENT: What kind of environment do you include, is it a very clean environment or is it a normal, healthy, mouse or rat environment? DR BARAM: Angela, this is a wonderful British way of asking what is the role of early life exposure to a variety of bugs in terms of the conditioning of our immune system, and I think it is a wonderful, wonderful question, in my own experiments, we-royally because we decided to do both, we looked at both very clean and less clean and didn't see much of a difference early in life. However, we did have a situation where we add pinworm in the colony that causes brain inflammation and all of the control rats had-discharge and spike waves on them, and that was a total disaster, so yes, there is no doubt that exposure to a whole slew of inflammatory processes, including those in rodents caused by pinworm, which may also be something that is relevant to human, can cause very abnormal EEG and inflame the brain, but by and large at least the majority of studies that were discussed are valid across the spectrum of environments, so it is not necessarily a clean, sterilized, like in the natural environment. Wonderful question.
Therapeutic Targets and Translational Opportunities Current State of the Art Shlomo Shinnar, MD, PhD, Montefiore Medical Center. Dr Shinnar focused on current state-of-the-art treatments for epileptic encephalopathies. Many of these conditions are generally medically refractory from the onset. Treatment is often not with conventional antiepileptic drugs, and hormonal therapy plays a prominent role. The difference between epileptic encephalopathies and other epilepsies is that the goal is not just to control seizures but to prevent or reverse neurologic loss of functions, and this is one of the few settings where actually treating the EEG may be important.
With regard to infantile spasms, in the American Academy of Neurology and Child Neurology Society practice parameter, a responder is characterized by complete cessation of spasms as confirmed by video EEG and abolition of hypsarrhythmia on prolonged EEG. This practice parameter definition of response as an "all-or-none" phenomenon is very different from the usual definition of 50% reduction in seizures and is very different from the definition of efficacy when doing clinical trials to get FDA approval for antiepileptic drugs. It reflects the current understanding of the pathophysiology of the disease and recognition that unless the hypsarrhythmia is abolished, there is progression and cognitive decline.
In a study by Baram and colleagues in 1996 comparing highdose adrenocorticotropic hormone and prednisone, adrenocorticotropic hormone was superior, and even with a small sample, the effect size was so large that it was statistically significant. Additionally, several open-label studies by Sneed and colleagues using this regimen reported similar responses confirmed by video EEG. For further biological plausibility, if there was failure of prednisone, there was response to lowdose adrenocorticotropic hormone with almost the same rate.
Oral steroids likely have efficacy but the data are unclear. In randomized controlled trials, high-dose adrenocorticotropic hormone has consistently been superior. Low-dose adrenocorticotropic hormone, in contrast, has not been superior to highdose prednisone. UKISS did not use video EEG and used very low-dose adrenocorticotropic hormone. A recent study by Hussain and colleagues did show an improved response rate using the UKISS regimen confirmed by video EEG. However, even in that trial some of the failures responded to high-dose adrenocorticotropic hormone. While there are brain receptors for adrenocorticotropic hormone, it penetrates the blood-brain barrier poorly. Therefore, to maximally stimulate the adrenal gland, if assuming that is how it works, high-dose adrenocorticotropic hormone is not necessary since low doses maximally stimulate the adrenal gland. If, however, it is assumed that a direct action on the central nervous system is needed, a highdose regimen must be used and studies should reflect this and compare high-dose adrenocorticotropic hormone versus oral steroids, which many do not.
Studies have also shown that treatment with adrenocorticotropic hormone (whether cryptogenic or symptomatic) within the first month not only has a higher response rate but also a lower relapse rate. The relapse rate was 4% if treated within a month and 21% if treated after a month. Adrenocorticotropic hormone also produces favorable cognitive outcomes. In cryptogenic cases treated early, there is a high rate of long-term normal outcome, with normal being defined as normal intelligence, no seizure disorder, and on no medications.
Another treatment for infantile spasms, as previously discussed, is vigabatrin. In the American Academy of Neurology/ Child Neurology Society practice parameter, vigabatrin is possibly effective for short-term treatment of infantile spasms, with particular efficacy in tuberous sclerosis. There are concerns with this drug causing retinal toxicity. There have been many randomized trials, and the results show resolution of the illusion of spasms in 35% and resolution of spasms and hypsarrhythmia in 25%, which is not as good as adrenocorticotropic hormone. In other randomized trials, there is a varying response rate, but in tuberous sclerosis specifically there seems to be a very high response rate, for reasons that are not yet completely understood, making it the drug of choice in these patients.
In comparing hormonal therapy versus vigabatrin, the UKISS study showed that efficacy was better with hormonal therapy, with primary outcome being clinical cessation of spasms. This study excluded patients with tuberous sclerosis, where vigabatrin has been proven to be most effective. Cognitive outcomes in cryptogenic cases at 12 to 14 months were better in those who received hormonal therapy as well.
In regard to initial treatment with dietary therapy, the ketogenic diet was not as effective at stopping spasms or normalizing the EEG as adrenocorticotropic hormone, and should therefore not be used as first-line treatment for spasms.
In recent recommendations by the International League Against Epilepsy for management of infantile spasms, adrenocorticotropic hormone is the first-line therapy with Level B evidence for infantile spasms (excluding tuberous sclerosis). Alternative options that should be considered for infants with static severe neural insult and no regression are oral steroids, vigabatrin, and valproate. For infantile spasms in those with tuberous sclerosis, vigabatrin is considered the first-line therapy.
Surgical treatment is only available for a small portion who have focal lesions, whether found to be MRI-positive, PETpositive, or confirmed using other means of identification. In these few cases, there yields a substantial number of seizurefree patients. Surgery in most of these cases includes either hemispherectomy or multilobal resection, such as the temporal occipital parietal procedure.
Further studies are required to determine the optimal treatment of children with infantile spasms. Further studies of new agents and antiepileptic drugs are required to assess their efficacies. Development of animal models can help identify novel targets for therapeutic development. Long-term measures should include cognitive outcomes using standardized psychometric assessments. Standardized dosage and duration of treatment are essential to allow comparison of short-and long-term outcomes.
In Lennox-Gastaut syndrome, valproate is the historical first-choice therapy, although it is not FDA-approved specifically for the condition. However, when looking at the seizure types it is approved for, such as atypical absence and myoclonic seizures, these are patients with Lennox-Gastaut syndrome. The US FDA-approved drugs include clobazam, clonazepam, felbamate, lamotrigine, rufinamide, and topiramate. All these treatments are effective by definition of standard efficacy, which is 50% reduction of seizures. However, less than 10% of patients with Lennox-Gastaut syndrome treated with these medications become seizure-free. Furthermore, there are no comparative trials among these drugs to guide which ones should be used, and none of these drugs has shown any efficacy at preventing the long-term decline associated with Lennox-Gastaut syndrome. These treatments do not affect the associated slow cognitive decline. Cognitive and behavioral outcomes have not been outcome variables in any of the drug trials and are needed to help in choosing the best treatments.
Steroids, adrenocorticotropic hormone, and intravenous immunoglobulin have been reported to be effective, especially early on in the course of the condition; however, there are no randomized clinical trials but only small case series reporting some benefit. The ketogenic diet has had its most reported successes in cases of Lennox-Gastaut syndrome, with a seizure freedom rate at about 10% or better, which is at least as effective as any of the medical therapies. Other dietary options, including the Atkins diet and the low glycemic index diet, are more tolerated and thus more popular, but the data supporting their use are much less rigorous. Surgical options, for the small number of those eligible with the etiology of spasms matching etiologies of Lennox-Gastaut, include vagus nerve stimulation, complete corpus callostomy, and lesionectomy/lobectomy.
In treatment of electric status epilepticus in sleep, studies have looked at both the cognitive domain and the EEG improvement, defined as 25% reduction in spike-wave index with several different treatments. The most effective was focal resective surgery in those with a focal lesion. After that, steroids had the highest efficacy rate on cognition and EEG. Benzodiazepines of various types were next. Classic antiepileptic drugs were the least effective, although the most used. A future study that will be done in Europe will compare the efficacy of steroids: methylprednisolone pulse therapy IV or oral prednisolone and clobazam. The primary outcome will be cognition and the secondary outcome will be EEG seizure, safety, and tolerability.
In autoimmune encephalopathies, as with epileptic encephalopathies, treatment is aimed at more than just treating the seizures. The EEG is actually often encephalopathic, and there is an associated decline in neurologic function. There are no evidence-based consensus guidelines for treatment of autoimmune encephalopathies. Seizures are treated with the appropriate antiepileptic drugs, but the mainstay of treatment, since it is autoimmune in origin, are immune therapies. The first-line treatments are corticosteroids, gammaglobulins, and plasmapheresis, while second-line treatments are cyclophosphamide and rituximab. There is currently a need for randomized controlled trials to determine optimal therapy; however, this is hindered by the relative rarity of cases, the lack of clarity as to whether this class is homogeneous, and the fact that the diagnosis is often made late in the course, which complicates treatment.
In conclusion, while epileptic encephalopathies are a small proportion of all epilepsy, they account for a disproportionate amount of intractable epilepsy, with adverse effects on cognition and quality of life, a higher rate of sudden unexpected death from epilepsy, and an increased economic burden on families. Better evidence-based guidelines are needed for treatment of these disorders. Novel therapies are very much needed and treatments are needed not just for the seizures but to improve overall neurologic outcomes, especially cognition and behavior.
Targeting the mTOR Pathway for Epileptic Encephalopathies
Michael Wong, MD, PhD, Washington University School of Medicine. Dr Wong discussed the mechanistic/mammalian target of rapamycin (mTOR) pathway relevant to both tuberous sclerosis and to other types of epilepsy, including nongenetic epilepsies. He began by highlighting the limitations of current antiseizure medications. One-third of all epilepsy patients have uncontrolled seizures despite appropriate management with current medications and nonmedical therapies. Also, current treatments are primarily symptomatic therapies that suppress seizures but do not have disease-modifying or antiepileptogenic properties to prevent the development or progression of epilepsy. Although most of these drugs have different mechanisms of action, overall most standard antiseizure medications act in a very similar way, by trying to reduce neuronal excitability directly, usually by modulating ion channels or neurotransmitter receptors. As such, to generate better drugs, different mechanisms of action need to be explored.
In thinking of rational strategies for targeting specific mechanisms of epilepsy in the brain, it is important to think of the common sequence of events in the brain during epileptogenesis. It usually starts with the etiology, also known as the initial precipitating brain injury. This can mean a classic acquired injury, like a stroke or a head trauma, but it could also be a genetic defect or mutation that affects the brain. After the initial injury there is usually a period of time called the latent period of epileptogenesis, which can last months to years, during which there are no seizures, so the patient does not yet have epilepsy. However, abnormal changes are already occurring in the brain that help promote transition to the epileptic state. Finally, at some point, significant, perhaps permanent, changes occur in the brain that lead directly to increased neuronal excitability and the expression of seizures, and now the patient does have epilepsy.
In trying to develop better therapies, different mechanisms along the sequence of events should be targeted. Ideally, primary prevention would be the best approach if the different causes of epilepsy could be prevented from happening, although this is not often feasible. As previously mentioned, most current antiseizure medications appear to act against the end-stage symptoms of epilepsy, the seizures themselves, primarily by directly decreasing neuronal excitability, by modulating channels and neural transmitter systems. Again, these drugs are ineffective in many cases and they don't appear to have disease-modifying effects or preventive effects, so to develop better therapies other mechanisms of action should be targeted, perhaps more upstream during the latent period to affect some of these other epileptogenic mechanisms. For example, one rational strategy would be to target cell signaling pathways that are initially triggered by the different etiologies and then in turn can activate other downstream mechanisms causing epilepsy. The mTOR pathway does represent a rational target and may be involved in different types of epilepsy, including epileptic encephalopathies.
Tuberous sclerosis complex is a genetic disorder in which mTOR has been implicated in pathophysiology. It involves the formation of different tumors or hematomas in different organs. In the brain, there are the classic cortical tubers that give the disease its name, which are basically developmental malformations. However, there may also be brain tumors that grow, like subependymal giant cell astrocytomas. Different tumors can cause symptoms referable to different organs, but neurologic involvement usually accounts for the most disabling symptoms of disease, including epilepsy, developmental delay, and autism.
Epilepsy is very common in tuberous sclerosis complex, occurring in up to 90% of patients, and in many cases it is epileptic encephalopathy. The seizures typically start very early, often in the first year of life. They are usually very severe, they can be multiple types, and they are strongly linked or correlated with encephalopathy, with developmental delay. Infantile spasms occur in about a third of tuberous sclerosis complex patients and more than two-thirds of these are drugresistant, compared with the roughly one-third rate in the general epilepsy population. The one notable exception is vigabatrin, which appears to be very effective in infantile spasm in tuberous sclerosis complex, for unclear reasons. However, even if spasms resolve, most of the tuberous sclerosis complex patients go on to develop other seizure types that are drugresistant. Some patients are candidates for epilepsy surgery, but many tuberous sclerosis complex patients are not good surgical candidates, and, therefore, more effective therapies are needed to help these tuberous sclerosis complex patients with epilepsy.
In addition to the issue of drug resistance, again similar to all types of epilepsy, there has not been a proven preventive therapy to prevent epilepsy in tuberous sclerosis complex. However, tuberous sclerosis complex may actually represent a model disease for trying to develop a preventive therapy, because to prevent epilepsy, one must identify at-risk patients ahead of time, before they start having seizures. A significant subset of tuberous sclerosis complex patients are diagnosed with the condition during infancy, such as due to cardiac tumors, before they start having seizures, and they are considered high-risk patients, as up to 90% will go on to develop epilepsy. This would, therefore, represent a rational, feasible population to target with a potential preventive therapy.
Second, specific mechanisms of epilepsy in the brain that can be targeted must be identified at an early mechanistic stage. In tuberous sclerosis complex, the mTOR pathway does represent a potential target for antiepileptogenesis. Two genes that cause tuberous sclerosis, TSC1 and TSC2, have been identified, and they encode the proteins hamartin and tuberin, which are known to bind together to form a complex, which together inhibits the mTOR pathway. mTOR is basically a protein kinase, which is very ubiquitous, and it is involved in a number of important normal cellular functions such as cell growth, proliferation, and metabolism, as well as brain-specific functions.
On the biochemical level, mTOR activates a number of downstream mechanisms, which primarily regulate protein synthesis related to these various functions. Normally the TSC genes, hamartin, and tuberin act to dampen mTOR activity and thus prevent excessive cell growth and proliferation and inhibit other functions, but in the disease of tuberous sclerosis, mutation of either TSC1 or TSC2 lead to a decrease in the hamartintuberin complex, which can cause a disinhibition or hyperactivation of mTOR. This will, among other things, cause increased cell growth and proliferation and can explain why tumors form in tuberous sclerosis complex. mTOR stands for mechanistic or mammalian target of rapamycin because it was discovered as the drug target of rapamycin. Rapamycin was originally approved as an immunosuppressant drug. mTOR inhibitors, such as rapamycin, could therefore potentially directly counteract the effects of tuberous sclerosis complex mutations by inhibiting mTOR and thus inhibiting cell growth and proliferation. Clinical trials have shown that mTOR inhibitors like rapamycin or everolimus (rapamycin analog) are effective against brain and kidney tumors in tuberous sclerosis complex patients, leading to FDA approval of everolimus for these indications in the last several years.
While the mTOR pathway clearly represents a rational effective target for treating tumors in tuberous sclerosis complex, it is not as clear whether this is related to epilepsy in tuberous sclerosis complex. Mechanisms of epilepsy are not as well understood as tumors in this disease. Epilepsy in general is not directly related to tumor growth; however, it might be related to these static developmental lesions, the cortical tubers. The tubers, which are focal cortical malformations, do not grow like tumors. They consist of focal areas of abnormal cortical lamination, astrogliosis, and a variety of abnormal cell types, dysmorphic neurons, and classic giant cells, which have immature features. It is often believed that seizures in tuberous sclerosis complex are somehow caused by the tubers, because surgical removal of tubers can sometimes eliminate seizures in some of these patients. However, even in these cases it is often debated as to whether the seizure is starting within the tubers themselves or perhaps from the more normal-appearing areas of the cortex surrounding the tubers, the so-called perituberal region. In some cases, the seizures may be completely unrelated to any specific lesions.
With regard to the mTOR pathway, similar to tumerogenesis, it is very feasible that abnormal mTOR activity could drive a number of downstream mechanisms on the circuit down to the molecular level that all contribute to epilepsy. This is especially true given what is already known about mTOR's normal function in regulating processes, such as cell growth and protein synthesis, which can cause dysregulation of different ion channels and neurotransmitter receptors. Therefore, if accurate, rapamycin or other mTOR inhibitors would represent a rational therapy for epilepsy in tuberous sclerosis complex.
There are already substantial preclinical data from animal models of tuberous sclerosis complex that mTOR is involved in epilepsy and that mTOR inhibitors effectively reduce seizures and have potential preventive effects, when started early. A number of different animal models of tuberous sclerosis complex have been generated involving inactivation of TSC1 or TSC2 in different cell types in the brain leading to seizures. One model involves conditional inactivation of the TSC1 gene, predominantly in glial cells in mice. These mice appear grossly normal for the first month of life, but then they develop seizures that become progressively more frequent, with 9-week-old mice averaging about 10 seizures a day. The mice then become very sick and start dying, with all mice dying by about 3 to 4 months of age. In addition to the seizures, the interictal EEG also becomes progressively abnormal, with increased spike discharges, and slowing of the background often culminating in a burst-suppression pattern, likely consistent with progressive epileptic encephalopathy.
With regard to the mechanisms of epilepsy in these knockout mice, their brains exhibit gross diffuse progressive glial proliferation, as seen by increased numbers of glial fibrillary acidic protein-labeled astrocytes. This is presumably due to increased mTOR activation caused by knockout of the TSC1 gene in the astrocytes, and this leads to very obvious megalencephaly of the brain. It is diffuse increased brain size, which is due to the increased glial cells, both the size and growth of the glial cells or the proliferation. There are no focal abnormalities just of tubers, but there is also neuronal disorganization with dispersion of the parietal cell layers within hippocampus. These kinds of gross pathologic abnormalities could certainly effect neuronal excitability in seizures on the circuit or network level.
On the molecular level, a hypothesis that proposed that impaired astrocyte regulation of glutamate may contribute to epilepsy was tested. Glutamate, the major excitatory neurotransmitter in the brain, is released into synapses to activate postsynaptic neurons. Astrocytes normally contain specific glutamate transporters called GLP1 and GLAST, which help remove glutamate from the synapse and terminate the synaptic signal, so the tuberous sclerosis complex genes can potentially regulate expression of these glutamate transmitters through the mTOR pathway. If there were a defect in these glutamate transporters, this could lead to elevated extracellular glutamate levels. This, in turn, could cause excessive excitation of neurons and cytotoxic cell death, which could both promote epilepsy.
In knockout mice, the expression of glutamate transporters in the astrocytes is decreased, and this is correlated with extracellular glutamate levels as well as excitotoxic cell death. Pharmacologic methods can be used to induce glutamate transporter expression in the knockout mice and restore normal levels, and this will inhibit seizures at least partially in the knockout mice, suggesting that this glutamate mechanism is pathogenic in these mice.
Thus, a number of mechanisms on the circuit, cellular, and molecular levels that may all contribute to epilepsy have been identified. All of these could potentially be downstream from mTOR; therefore, to test directly the role of mTOR in the epilepsy of these mice, the effect of rapamycin on epilepsy has been tested. Downstream phosphorylation of S6 protein was used as a readout of mTOR kinase activity, so knockout mice have increased mTOR activity compared with control mice and rapamycin treatment can inhibit this mTOR activation.
Two treatment paradigms of rapamycin were used, including early preventive antiepileptogenic paradigm and a late, symptomatic antiseizure paradigm. In the early paradigm, mice were treated starting at 2 weeks of age. This is before the onset of seizures in the mice. Early rapamycin treatment can prevent the pathologic abnormalities seen in the mice, most notably the increased numbers of glial fibrillary acidic protein-positive astrocytes and the corresponding megalencephaly of the brain. On the molecular level, rapamycin treatment can at least partially restore normal GLT-1 glutamate transporter levels, and then, most remarkably, early rapamycin treatment can prevent the development of epilepsy.
Treatment with rapamycin starting at 2 weeks of age can completely block the development of epilepsy in these mice and also greatly prolongs their survival, basically as long as they are treated, up to 6 months in this experiment. Of note, if the rapamycin is stopped at this point, the phenotype will emerge with seizures and death. Therefore, rapamycin is not a cure and does not correct the underlying genetic defect that is driving mTOR hyperactivation. However, as long as rapamycin is started early and maintained, it appears to completely prevent development of the neurologic phenotype of these mice, the epilepsy, the premature death, and, importantly, the underlying pathologic and molecular abnormalities that drive epilepsy of these mice, consistent with an antiepileptogenic effect.
Late rapamycin treatment, starting at 6 weeks of age, which is after onset of seizures in most mice, also can reduce seizures and prolong survival. Again, similar effects of rapamycin or other mTOR inhibitors have been reported in other knockout mouse models of tuberous sclerosis complex as well as the closely related P10 knockout mice. Therefore, the preclinical data are pretty consistent and compelling, suggesting that mTOR is involved and mTOR inhibitors are effective. This is starting to be translated to patients, and findings from a number of uncontrolled trials or reports have been published in the literature. One uncontrolled trial in particular by Franz and colleagues suggests that everolimus treatment, which is an mTOR inhibitor, can decrease seizure frequency in tuberous sclerosis complex patients with drug-resistant epilepsy.
Dr Wong then moved away from tuberous sclerosis complex and elaborated on an expanded version of the mTOR pathway. Mutations have been discovered in patients with hemimegalencephaly, focal cord dysplasia, and a number of other syndromes involving epilepsy and cortical malformations. Many of these are epileptic encephalopathies, and therefore, mTOR inhibitors could be used as potential treatment for these conditions, although there are very little data supporting that at this point.
Most of these genetic disorders are quite rare, and a more interesting question is whether mTOR is involved in other more common types of epilepsy, such as acquired epilepsy due to brain injury. In these cases, mTOR could potentially be activated by a number of different upstream pathologic stimuli, genetic or nongenetic, and, in turn, can activate downstream mechanisms that are involved in epilepsy in different conditions. This is starting to be looked at in a number of animal models of acquired epilepsy. There are classic status epilepticus models, where rapamycin has been reported to have some beneficial effects in some of these models, although not in others.
Similarly, in infantile spasms models, there is at least one model where rapamycin had some effect as well as a model of neonatal hypoxia. Posttraumatic epilepsy due to traumatic brain injury is perhaps one of the most clinically relevant forms of epilepsy and it is also amenable to a preventive approach because there is often a long latent period between the head trauma and the subsequent development of head trauma. In a study by Staley and colleagues, it was reported that rapamycin has antiepileptogenic effects in an in vitro model of posttraumatic epilepsy. Dr Wong's lab has looked at an in vivo model of traumatic brain injury that was a controlled cortical impact model, where a hole was created in the cortex, and some of these mice developed posttraumatic epilepsy. Controlled cortical impact injury leads to abnormal activation of the mTOR pathway and rapamycin treatment started right after the injury can block that period of mTOR activation.
A number of pathologic changes occur in these traumatic brain injury models that may contribute to epilepsy. One example is mossy fiber sprouting, where the granule cells in the hippocampus cause recurrent synapses to form on themselves through the multifibers, which is thought to set up excitatory recurrent circuits that drive seizures. Rapamycin can at least partially reverse some of this mossy fiber sprouting and can decrease the development of posttraumatic epilepsy, both the incidence of posttraumatic epilepsy and the seizure frequency.
In summary, the mTOR pathway is critical for epileptogenesis in mouse models of tuberous sclerosis complex and other genetic mTORopathies, and mTOR inhibitors have both preventive antiepileptogenic and symptomatic antiseizure effects on epilepsy in these models. The mTOR pathway also may be involved in epileptogenesis in animal models of acquired epilepsies due to brain injury, although the effects of rapamycin are more variable. An mTOR inhibitor is an approved therapy for tumors in tuberous sclerosis complex patients and is being tested for intractable seizures in clinical trials of these patients. Testing the potential antiepileptogenic effects of mTOR inhibitors for preventing epilepsy in tuberous sclerosis complex patients is rational and feasible.
Cannabinoids
Amy Brooks-Kayal, MD, Children's Hospital Colorado. Dr BrooksKayal focused her discussion on the cannabinoid system, its biology and current evidence about the therapeutic use of cannabinoids in epilepsy as well as adverse effects. Cannabis is a genus of plants containing several species. There are several active compounds in these plants that include the cannabinoids, and the cannabinoids that come from plants are referred to as phytocannabinoids. Tetrahydrocannabinol is the main psychoactive component of phytocannabinoids. Cannabidiol is the nonpsychoactive component that has raised much interest related to potential use in epilepsy. There is an endogenous brain substance, endocannabinoids, that works on the same system, and there are also synthesized cannabinoids. Hemp is a plant in the cannabis family with very low levels of tetrahydrocannabinol, less than 0.2% to 0.3%, and is regulated very differently than marijuana products.
The phytocannabinoids, including cannabidiol and tetrahydrocannabinol, both come from the same precursor known as cannabigerolic acid, but once they become cannabidiol and tetrahydrocannabinol, they never cross-react and become each other. The endocannabinoids again are derived from arachidonic acid, and these are the endogenous ligands of the cannabinoid system in the brain. They are a very active system within the brain and are very rapidly synthesized, activated, and degraded. They are designed to provide on-demand regulation of neurons; they act at both excitatory and inhibitory synapses, via several types of cannabinoid receptors, but the cannabinoid receptor 1 is best known and most highly expressed in the brain.
After their release, the endocannabinoids travel retrograde back to the presynaptic membrane, where they bind again to cannabinoid receptors, primarily cannabinoid receptor 1. Cannabinoid receptor 1 is the most abundant G protein-linked receptor in the brain, and it is abundant in many areas of the brain believed to be central for epilepsy, such as the hippocampus and cortex. Once bound to the receptor, a number of downstream effects influence the activity of neurons; the opening of calcium channels; the opening of potassium channels; the activation of calcium channels; the inhibition of adenylcyclase, which activates a number of downstream signaling pathways in the brain; the stimulation of kinases that can modify proteins that can have significant effects on neuronal activity; and also inhibition of neurotransmitter release. This inhibition of neurotransmitter release can have very different effects depending on whether it is affecting excitatory or inhibitory synapses.
In addition to the effects on the endocannabinoid system and cannabinoid receptors, phytocannabinoids also have an effect on a number of other very important transmitter systems in the brain, including the TRPV channels and serotonin receptors. Phytocannabinoids, therefore, have a dramatic effect on a number of different molecular mechanisms in the brain, and, not surprisingly, they have been found in turn to have a significant effect in preclinical models on a number of different models of epilepsy.
Recently, there were 4 trials, all with very low numbers, all of which were basically uncontrolled and were considered Class IV evidence. In those trials, 2 of the 4 studies showed any evidence of improvement with treatment with a variety of different cannabinoids. In a survey of children with treatmentresistant epilepsy on Facebook, 84% of families reported a benefit. However, this was a parental survey on Facebook and fully uncontrolled, using artisanal compounds. Based on this, the recent Cochrane Review said there was no reliable conclusion that could be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy. There has also been a recent systematic review by the American Academy of Neurology. A very similar position has been taken by the American Epilepsy Society, the American Academy of Pediatrics, and the American Medical Association, all stating that at this time there is insufficient evidence to recommend cannabinoids for the treatment of epilepsy.
Currently, there are ongoing studies, one of which is an Epidiolex study. This is a purified cannabidiol or cannabidiol compound that is plant-derived. It is made by GW Pharmaceuticals from the United Kingdom, and an open-label compassionate use prospective observational study of 137 patients has just been completed. This involved multiple sites with children and adults with a variety of epilepsy types, but mostly severe intractable epilepsies. About 51% of subjects had a greater than 50% reduction in seizure frequency, considered an indication of a responder to a therapy in epilepsy. The median was about 54%; only 9% of the patients became seizure-free, 16% of whom were Dravet patients. There was a slightly larger effect on drop seizures than other seizure types. There were also a number of adverse effects, particularly somnolence, diarrhea, fatigue, and decreased appetite. There were no major changes to blood or renal markers, but there were serious adverse effects that in 22 patients were thought to be possibly related to the cannabidiol treatment, and these included status epilepticus, diarrhea, weight loss, pneumonia, and hepatotoxicity.
Epidiolex is currently in phase 2 and phase 3 studies for Dravet syndrome and Lennox-Gastaut syndrome. It is going to be multicentered and researchers are going to evaluate different doses, pharmacokinetics, and drug interactions, including the interaction with clobazam, where there has been a reported increase in the desclobazam metabolite. There is also a study with synthetic cannabidiol; some phase 1 and phase 2 studies have been completed. There is another study of cannabidiol that is in phase 1.
With regard to central nervous system toxicity with the use of cannabinoids in the treatment of children with epilepsy, current available data are either preclinical or from adult recreational use. In monkeys exposed to marijuana, structural changes in the brain have been observed, and recreational use of marijuana in humans can also result in structural changes in the brain as well as functional changes seen in functional MRI studies. There have been some diffusion tensor imaging studies associated with changes in frontal connectivity that may be associated with increased impulsivity. In a recent study, it was found that early cannabis users had smaller brain volumes, which raises concerns about what potential effects may be seen when cannabinoids are being used in younger patients.
As far as learning and memory are concerned, the cannabinoid system has a dramatic effect on long-term potentiation, which is one of the cellular bases for learning. In fact, one of the tetrahydrocannabinols and some of the other cannabinoids are known to prevent long-term potentiation from occurring and impair hippocampal-dependent learning and memory. Systemic administration of cannabinoid receptor 1 agonist, working on the endocannabinoid system, impairs the normal firing of hippocampal neuronal assemblies, which plays a role in learning and memory. Adolescent animals exposed to tetrahydrocannabinol had more cognitive impairment than adult animals exposed to them.
Similarly, human multiple sclerosis patients who were using marijuana products for therapeutic purposes experienced deterioration in a number of performance measures, including processing speed, working memory, executive function, and visual-spatial perception. There are conflicting data regarding the persistence of impairment in community users; however, there is a study suggesting that in younger recreational users, even after recreational marijuana use has stopped, there continues to be up to a 10-point decline in IQ and a grade-level reduction in academic performance.
Psychiatric concerns have also been raised about this. There seems to be an increased risk for schizophrenia in users of recreational marijuana and that may be related to an underlying genetic susceptibility, and depression also seems to be higher in adolescents who use marijuana. This raises the question of whether the use itself is increasing the risk or whether the use is a result of self-medicating because of psychiatric disorders. In other studies, early usage of marijuana products also has been associated with disruption of sleep, and in one case, some increased incidence of stroke with the use of cannabinoid receptor 1 analogs.
With regard to FDA scheduling of these products, some current cannabinoid products are Schedule 2, including Cesamet, which is a synthetic tetrahydrocannabinol, or even Schedule 3, such as Marinal, which is a synthetic delta tetrahydrocannabinol and is psychoactive. Cannabidiol, which is again considered nonpsychoactive, is being studied and has to be studied under Schedule 1. According to the FDA, Schedule 1 includes compounds that have no medical or therapeutic uses and have very high abuse potential. It is, therefore, unclear as to why cannabidiol would be considered to have a higher abuse potential than tetrahydrocannabinol, and considering it is in trial why it would be considered to have no medical therapeutic potential.
Many states have taken it upon themselves to regulate the use of medical marijuana locally. In total, 18 states at this point have laws that specifically permit use of high-cannabidiol products in addition to states like Colorado and California that allow more broad use of medical marijuana products. Several states have additional laws under consideration or laws that are stalled in legislation. What is considered cannabidiol varies; anywhere from 0.3% to 0.5% tetrahydrocannabinol can be allowed under some of these state laws and still be considered a high-cannabidiol product. Most states have no specific provision for how the compounds are made or processed or even if there is in-state production, so a number of states have said it is legal to possess it but illegal to buy it within the state. Some states have limited production within state-permitted or stateapproved facilities like state universities or academic institutions. Other states have said it is fine to have it, but must be one of the pharmaceutical products that is under study using FDA guidelines.
In August 2013, the deputy attorney general of the US Department of Justice decided to defer to state law enforcement and regulatory agencies regarding recreational and medical marijuana, provided they have in place strict regulatory systems to ensure compliance with particular priority areas.
Two bills are pending in Congress, including a compassionate access research expansion bill that is in the Senate and another version that is in the House that would reschedule cannabis to lift federal barriers to research and protect individual states with medical cannabis programs. There is also a Charlotte's Web medical access bill that is in the house that would improve access to artisanal compounds and protect individuals and families who are using this cannabidiol oil.
In Colorado, in November 2000, the state constitution was amended to allow the prescribing of medical marijuana for persons suffering from debilitating medical conditions. The state health agency provides a red card to people who are residents of Colorado; have a valid Social Security numbers; have one of the many qualifying medical conditions, which include seizures; and have a therapeutic relationship with a physician. Those under 18 years of age need 2 doctors to sign off on that. Currently, there have been almost 290,000 applications for medical marijuana; 116,000 people currently have access to marijuana in the state of Colorado through this program, most are adults and most are male. There are about 450 children who currently have red cards in Colorado and, again, a number of conditions are approved, with epilepsy as the minority of that. It is mostly for cancer and pain.
Medical marijuana has posed unique challenges for medical providers in Colorado, including a significant increase in call volumes asking about information on medical marijuana, influx of medically complex refractory epilepsy patients, and an increase in accidental ingestion in the emergency department. Additionally, pharmacies cannot store or dispense marijuana products; there are a lack of data on safety, efficacy, pharmacokinetics, and drug interactions; and there is no standardization of content, quality, or purity of products. As a result, providers do not prescribe marijuana products outside of clinical trials.
Previously, at the Children's Hospital of Colorado, there have been 113 patients, 75 of whom were recently reported. In 33% of these patients, there was a significant response based entirely on parental report of greater than 50% reduction in seizures. It seemed to work better in Lennox-Gastaut syndrome than some of the other severe seizure types. However, there was no corresponding improvement in EEG in those children in whom they were able to check. There was no notable difference in the product that was used, and the single biggest predictor of whether a family felt it was effective was whether they had moved in from out of state. In terms of other improvements, families thought that sometimes a number of other factors in their children were improved, such as alertness, behavior, language and motor skills, and sleep. Forty-four percent had adverse side effects such as increased or new seizures, somnolence or fatigue, gastrointestinal symptoms, irritability, developmental regression, and abnormal movements, and in a similar distribution to what was seen in the observational study using Epidiolex.
The Children's Hospital of Colorado has developed a clear treatment protocol. They do not recommend use of cannabinoids for treatment of epilepsy outside of clinical trial. Baseline laboratories are done prior to use and every 4 weeks, including, importantly, trough antiseizure levels of all measurable medications, including clobazam and its metabolites. Families are encouraged to keep a seizure diary and to keep other medications unchanged, and, when possible, a pre-and post-therapy EEG is obtained.
To summarize, the cannabinoid system has significant representation in multiple brain regions, making it a promising target for therapeutics, but mechanisms are complex. Clinical data are available for some indications but data for epilepsy are still sparse and often poorly conducted; more research is needed. Extensive literature on potential toxicity highlights the need for safety monitoring, especially in children and adolescents. Regulatory measures are inconsistent and evolving, with differences at the state and federal level. Increased use of complementary and alternative medicine indicates an unmet therapeutic need and highlights the need to ask patients and families about this subject. Lastly, if patients and families are choosing to use complementary and alternative medicines, a standardized approach to assess safety and efficacy should be developed.
Epileptic Encephalopathies: Engineering Stem Cells for Therapeutics
Jack Parent, MD, University of Michigan. Dr Parent focused his discussion on engineering stem cells in applications for epileptic encephalopathies. Pluripotent stem cells are cells that can self-renew and give rise to all of the cells in the organism. The classic example is the embryonic stem cell that arises from the inner cell mass of the blastocyst and, when cultured in vitro, it can self-renew, expand, and give rise to all 3 germ layers: ectoderm, mesoderm, and endoderm.
Shinya generated the first induced pluripotent stem cell in mouse in 2006. He and Jami Thompson did the same in human in 2007. He found out how to reprogram a mature cell, such as a skin cell from a mouse or a human, by expressing these specific developmental transcription factors that reprogram the cells into a pluripotent state. When cultured in embryonic stem cell conditions, they form colonies that behave like pluripotent stem cells. They can give rise to any tissue and can be used for regenerative therapy. They can be studied in vitro, where they are useful to study the earliest mechanisms of human development and pluripotency as well as disease. Disease mechanisms can be studied in a dish, and test for drug toxicity on human cells and screen for new therapies for specific diseases.
When focusing on neurologic disorders, these induced pluripotent stem cells must be differentiated into neuro lineage cells. Typically, it takes several months to differentiate an induced pluripotent stem cell into different cell types. In work by Tom Sudoff, he showed that he could turn either induced pluripotent stem cells or embryonic stem cells from human into neurons within just several weeks, by overexpressing an excitatory cortical neuron developmental factor, neurogenin 2. He used human embryonic stem cells that expressed a neurexin mutation associated with autism and showed a synaptic phenotype in these cells. Induced pluripotent stem cells of patients with genetic mutations can be taken and the mutation corrected with gene editing, so that there are isogenic controls that only differ by the presence or absence of mutations, but otherwise all of the genes are separate. Genetic diseases where patient tissues cannot be accessed can also be studied by making virtual patients using the gene editing because the specific mutation can be put on a control line and again have control or mutant that differ only by the presence or absence of mutation.
To date, a number of different models of epilepsies have been generated from induced pluripotent stem cells from patients. These include several epileptic encephalopathies, including Dravet syndrome, Angelman syndrome, Rett syndrome from MECP2, as well as the variant from CDKL5; some autism spectrum disorders like Phelan-McDermid syndrome and Timothy syndrome; and fragile X. Notably, all of them have shown phenotypes to a variable extent in cultured neural cells from these patients, and some of the phenotypes have been able to be corrected with therapies for Timothy syndrome and Rett syndrome as well as Phelan-McDermid.
The epileptic encephalopathies studied in Dr Parent's laboratory include Dravet syndrome due to SCN1A and 1B mutations, SCN8A-related epilepsy, PCDH19-related epilepsy, polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (or Pretzel syndrome), as well as genetic epilepsy with febrile seizures due to SCN1B, fragile X, and neuroacanthocytosis. The approach involves taking a skin biopsy, reprogramming the skin cells to stem cells, making brain cells, and studying epilepsy. With this approach, comorbidities such as sudden unexpected death in epilepsy also can be studied. In addition to brain cells, other cell types can be formed, such as cardiac myocytes, autonomic neurons, and even brainstem neurons potentially to study potential mechanisms of sudden unexpected death in epilepsy and create treatments.
With regard to drug screening with patient-derived neurons, in some of the induced pluripotent stem models of neurologic disorders with epilepsy, including Timothy syndrome and Phelan-McDermid, researchers have found in vitro efficacy on these neurons and have gone to clinical trials based on that as well as animal work, including insulin growth factor-1. Kevin Eggins and colleagues used amyotrophic lateral sclerosis patient induced pluripotent stem cell-derived neurons to find a potassium channel defect that they could reverse with retigabine or ezogabine, which is going to clinical trials based on the findings of induced pluripotent stem cells in a dish. Lastly, some pediatric cardiologists are making cardiac myocytes from their patients' induced pluripotent stem cells, for example, in long QT syndrome, and are studying how certain channel blockers along with pacing rate are influenced in the cells and are using that to guide their treatment of arrhythmias.
In Dr Parent's laboratory, this is being applied to SCN8A-associated epilepsy. SCN8A is a voltage-gated sodium channel that causes an early infantile epileptic encephalopathy. There are some differences between SCN8A-associated epilepsy and Dravet syndrome in terms of the type of seizures and age of onset. SCN8A, unlike Dravet, is not temperature-sensitive, and has different antiepileptic drug responses. In the lab, a protocol was used to make excitatory neurons. CTIP2 was used as the marker of deep layer cortical projection neurons. They differentiated the patient-induced pluripotent stem cells into cortical projection neurons and used a fluorescent reporter driven by the CaMKII alpha promoter. Sodium currents were recorded of 2 clones from one patient with SCN8A and 1 clone from another patient with SCN8A that they made into neurons, and there was not much difference in the transient current. However, the persistent current was very low in the control and much higher in the patients.
This method is very laborious, and a more rapid method was needed to test drugs. As a result, researchers have chosen to use multiwell multielectrode arrays. They come in 12-well, 48-well, and 96-well plates, and they each have a number of electrodes per well. Researchers were able to observe real-time activity, each showing action potential activity in all of the wells, and measured this activity in a given well. Synchrony, bursting, spikes per well, spikes per electrode, and overall activity of patient-derived neurons can be measured. When this was done for 2 controls and 2 SCN8A patients, they saw over time that the activity increased in both groups. The 2 patients showed much greater activity than the controls, which is what is expected with a seizure phenotype hyperactivity. They then tested drugs on these cells and found that with oxcarbazepine, patients show increased suppression of activity over time with dose, more so than the control. The same was true for lamotrigine. Levetiracetam had no effect and riluzole seemed to suppress more for the control than for the patient. The next step is to test other antiepileptic drugs to do library screens to come up with new treatments as well as toxicity assays in the 96-well plates, looking with certain dyes at cell death. This is to ensure that the decreased activity is not just because the cells are being damaged. The goal is to use this for precision personalized therapy.
Dr Parent also discussed the work being done in his laboratory regarding cerebral organoids. Instead of culturing humaninduced pluripotent stem cells flat on the plate, they are grown in suspension, self-organize, and form mini brain-like structures. After 2 months of culture, big structures form that have a ventricular-like lumen. They have a ventricular zone that expresses neural stem cell markers like PAC6 or SOX2, and then they have a cortical mantle that expresses neuronal markers, such as TuJ1. At 2 months, there is a deep layer marker expressed CTIP2 but not superficial layer markers. By 4 months, however, there are both deep layer markers, CTIP2 and SATB2 superficial pyramidal cell markers, expressed. There are MAP2ABþ neuronal cortical mantle, new Npositive neurons, and GABAergic interneurons that are perhaps migrating up from the deep layer. From this they are able to make acute slices and record currents, sodium and potassium currents, and action potentials from these cells. The cells are still immature and the researchers are working on ways to get these to mature further. However, the cells have already been used to study certain diseases, including autosomal recessive primary microcephaly, and found a phenotype with the organoids. It is believed that in the future this can be used in epileptic encephalopathies, as a useful approach to look at mechanisms and to test for new therapies.
With regard to grafting of human pluripotent stem cells for epilepsy, the best cell types to use would likely be interneurons that inhibit excitatory cells. What progenitor stage is optimal for getting the cells to migrate, and for getting them to mature and integrate in vivo, has yet to be determined. Most work has suggested that median ganglionic energy progenitors are probably ideal, as they are likely the most migratory progenitor. Alvarez and colleagues showed that if injected in the brain of rodents, they migrate and form somatostatin interneurons, which inhibit excitatory neurons and control hyperexcitability.
In work done by Baraban and colleagues, medial ganglionic eminence from embryonic mouse was used. The cells were disassociated and they then made mice epileptic with the chemoconvulsant pylocarpine. Baraban injected the transplanted cells bilaterally into the hippocampi, which migrated up in each hemisphere, and then looked at both those with seizures and the controls. Most of the mice with medial ganglionic eminence cells into the hippocampus had no seizures, but the average was less than about 0.2 seizures per day, whereas if researchers injected into the amygdala they got no effect, so this was an important proof of principle with acquired epilepsy.
Another group from Harvard used the mouse pilocarpine model and used channelrhodopsin-labeled stem cells so that they could excite them in vivo and see if they integrated. They showed that the cells matured, but not fully. The cells integrated into the network, received host synapses onto them, and also reduced seizures from about 2 per day to about 0.3 per day. Therefore, it has been demonstrated as proof of principle on rodent models but there are some challenges left for this approach.
One key challenge is teratomas. When working with pluripotent stem cells, if they are differentiated but there are still remaining pluripotent stem cells, there is the potential to form teratomas when injected in vivo. The cells have not been shown to fully mature in vivo, and when looking 5 months after transplantation, they found integrated interneurons, but they didn't fully mature in terms of resting membrane potential and the morphology of the action potential. Better ways are needed to get them to mature. The cells follow human development, and therefore the human embryo takes many months to develop. These cells, even when transplanted in a rodent, still take many months to develop because they are human cells. There is widespread migration in rodent with medial ganglionic eminence-like progenitors, but only 2 mm. In a human with an epileptic encephalopathy, the cells must migrate all over, and that is a challenge that must be addressed in the future.
In summary, in the future, induced pluripotent stem cellderived neurons should be useful for identifying therapies for patients with epileptic encephalopathies and other epilepsies, mainly genetic epilepsies. Other induced pluripotent stem cellderived cell types may reveal mechanisms of sudden unexpected death in epilepsy. The organoid cultures may be useful for studying brain development in epileptic encephalopathy and coming up with treatment to normalize abnormal brain development. Lastly, progenitor grafting is a potential therapy for epilepsies.
Question-and-Answer Session. DR SEAN GORETSKY: This will be a question and mostly a comment, I'm Sean Goretsky from Saint Louis University, and after many hours and weeks of debates, we have been the only institution in Missouri that will be supporting cannabinoid use for our patients and I think what a tremendous forum to discuss this in. I think we need to remember the topic of the day, the epileptic encephalopathy. We spent all morning learning about the catastrophic nature of these disorders, we spent the beginning of this afternoon hearing about how lousy our treatment is for these, and so I think we have put a lot of time into the patients we will be supporting for this process. We realize, and Amy I certainly agree with everything that has been on the slides, it's very limited. I'm just wondering about the clinicians in the room that were skeptics by nature, but you know, how do we move forward when we know it is probably going to be years before we have good clinical data on safety and efficacy as we are seeing these patients come in. I think somebody needs to support these families and their cause, so I'm just curious what everybody's thoughts are on that front. DR BARAM: Thank you very much. I actually have a question to the panelists. So, we have heard about structural disorders generating epilepsy such as tuberous sclerosis and the molecular mechanism, we have also heard about IPS-well you add IPS cells, but I haven't really seen the true link, do you think there is a role for surgery and cell replacement in devastating multi-tuberous sclerosis? Can we take the stem cell therapy and use it to provide necessary enzymes to replenish horrible structural defects? Can we go not only to the near space but to the real outer space? DR PARENT: I'll defer to Mike Wong, the tuberous sclerosis guy, but I'll just say I think the big use right now is in studying disease mechanisms rather than cell replacement in vivo; there are a lot of issues with cell replacement so we are working on a line with Peter Kreeno that has mTOR hyperactivity due to strata alpha mutation, and we see nice phenotypes and we are going to be able to screen for better mTOR inhibitors, and I think that is going to be more useful than transplantation.
DR WONG: I'll just make a general comment. I think stem cells, mTOR inhibitors, whatever treatment you are talking about, it often comes down to timing, and so with tubular sclerosis, if the tubers are necessary or for apoptosis and once they form, which is basically first or second trimester, if you have an intervention and whether that is reversible or not that is the key question, so a lot does come out of timing.
DR BROOKS-KAHAL: Tallie, can I just respond to the comment that was made. I totally agree that we have to support these families. It was a hard decision, and we certainly decided that in the absence of the information that we need to safely prescribe we don't prescribe, but we absolutely as I mentioned work with these families. We have over 100 in our practice, and we work with them to do what we can to keep their children as safe as possible. You know, these are desperate families with very ill children and I think all of us deal with these families and understand that. I think the concern is that if we don't get these well-done studies done, we will never have the answers that we need.
I know it is hard to ask the families to wait a year for us to get the answers, but these studies are ongoing very quickly. The first phase 3s are probably going to finish enrollment the end of this year and we probably will have information within a year, at least enough information to start you know, being able to help these families more effectively. And if everybody goes out and tries artisanal products and we never get good data with the pharmaceutical grade products, these will never get FDAapproved, and what that means is families are going to continue having to pay out of pocket what can be $15,000 a year or more for some of these artisanal products and will never have the assurity of knowing necessarily what is in the products if the products are not made under GMP standards. So my heart goes out to these families, and I do share that with them when I meet with them, but to get the information that we need to do a really good job for these children now and in the future, we just have to show some patience, I think.
DR SHINNAR: I want to endorse what Amy said and elaborate on that. Yes, these are all our families that we all have as child neurologists who run epilepsy programs, they are heartbreaking, but I just want to remind people in the autism world there was this wonderful GI compound-that was the next miraculous drug and if you read the data on the web for it, it was at least as good. NIH had to spend millions of dollars to show it worked, as well as placebo. We are part of the cannabinoid trials, as is the Colorado group, and we are very enthused that it might be the next best thing, but we owe it to our patients to make sure it is not the next bust, and the early data look good, but we really just precisely because of the serious devastating long-term conditions, we owe it to our patients to have real data and not anecdotes before we endorse it for widespread clinical use outside clinical trials.
AUDIENCE: I have a question for Mike. I think you gave a beautiful example of how studying one gene or 2 genes, TSC1 and 2, can really illustrate gene-targeted and pathway-targeted treatments and extend that to FCD [phonetic] . So far all of the FCDs that we have looked at have been germline but mostly somatic mutations in the mTOR pathway. Along the same lines of the urgency that we feel about CBD, I think our clinical colleagues are very much feeling the urgency of OK, now that you know what these FCDs are and you keep telling us it's mTOR or AKT or one of these genes, when can we use rapamycin, how far are we from trials? I think we need trials, but how far do you think we are? DR WONG: With tuberous sclerosis we have the trials ongoing and the EXIST3 trial looking at Everolimus for intractable drug-resistant epilepsy in TSC; we should have results very soon. I kind of share the sentiments with my colleagues here, we need to find the data first before we start putting people on mTOR inhibitors and again the question about timing, I feel the earlier you can put someone on these drugs, the more effective it will be. I think mTOR prohibitors are probably more preventative than they are antiseizure. The mechanism for epileptogenesis versus seizure generation I think can be completely different, so-have any data about prevention again, but there is a symposium on Saturday to talk about how to design those trials, but those are very difficult trials to do, the preventative trials.
DR MARIA: My question has to do with targeting inflammation. We heard this morning, at least I heard, pervasive messages of ongoing inflammation and immune system engagement, so I was wondering with the therapies that were highlighted-either mTOR, cannabinoids, or the stem cellsor even with Dr Shinnar's review, current state of the art, what can we do beyond steroids that would get at the inflammatory contribution to injury if that is right, and do the novel therapies that were discussed, do they do anything with inflammation in the CNS? DR BARAM: Let me just take the moderator's prerogative and make one clarification. I think inflammation got a bad rap and what Sooky Koh tried to show is there are many components and many facets and some aspects of inflammation may very well be very good, so taking the sledgehammer approach may not necessarily work. People don't publish that; in fact, my group hasn't yet published that using massive doses of antiinflammatory postfebrile status epilepticus in an experimental model does not block epileptogenesis. The brain is a complicated entity. There is clearly a role as we have heard throughout the day for some aspects of inflammation, perhaps specific pathways such as L1 beta, where it is in a disease process. There may very well be and it's emerging that some aspects of inflammation are protective, adaptive, and what have you, so again there seems to be a recurrent theme. We probably need more information precisely on the components so that we can do precision medicine on it and really interfere selectively with some components of inflammation, and that may sort of set the stage for what people want to say.
DR SHINNAR: We need to remember that just because something appears to be a good idea it isn't. For many years steroids, aka brain juice and anti-inflammatories, were used in head trauma because of course it must be a good idea to prevent swelling and inflammation, until the randomized clinical trials were done showing the mortality was higher in the steroid-treated group. So I think we both need our basic science colleagues to give plausible targets, but just because it is a plausible target doesn't mean in the human brain it will work, and then we need to do good RCTs to actually demonstrate that this good idea actually works.
DR BROOKS-KAHAL: We heard from Mike that the mTOR pathway is very intricately involved in inflammation, and cannabinoids, as I mentioned, have a number of different biological activities and may have some anti-inflammatory as well as neuroprotective effects; our study for those effects related to some other processes-actually our studies are being considered in Europe and the UK so that may be one of the many mechanisms by which cannabinoids may work.
DR PARENT: Stem cells cure what ails you so-no, actually people were transplanting bone marrow stromal cells into brain for lots of different neurological disorders thinking, oh they are turning into neurons, replacing cells. They don't even survive, but they do have a transient anti-inflammatory effect that led to positive outcomes. Most of the stem cells secrete good cytokines that are anti-inflammatory.
Executive Summary of the Day
Brandy Fureman, PhD, NINDS/NIH. Session I covered the clinical aspects of epileptic encephalopathy. First, Dr Susan Koh discussed infantile spasms, defined as clusters of jerks over 10 to 20 minutes with a characteristic hypsarrhythmia on EEG. The etiology of infantile spasms is broad and the cause may be symptomatic or unknown; however, most common are hypoxic-ischemic encephalopathy and genetic causes. Etiology influences prognosis. There is frequent misdiagnosis and poor outcome may be related to delay in diagnosis; faster effective treatment has been shown to lead to better prognosis. The Infantile Spasms Prospective Database enrolling patients across the Pediatric Epilepsy Research Consortium is beginning to develop data on outcomes.
Next, Dr James Wheless discussed Lennox-Gastaut syndrome. He emphasized the diagnostic triad, including multiple seizure types, cognitive impairment, and abnormal EEG, and discussed that patients may not display all these features at the same time. In Lennox-Gastaut syndrome, which is typically diagnosed between 2 and 8 years (peak, 3-5 years), there is an elevated risk of mortality and of sudden unexpected death in epilepsy. The etiologies of Lennox-Gastaut syndrome are broad and it often begins with infantile spasms, clinical presentation can vary by etiology. New research directions in Lennox-Gastaut syndrome are focusing on the idea of multiple etiologies converging on a common network pathology; that there is significant brainstem and thalamus activation, which might present opportunities for new interventions. It allows Lennox-Gastaut syndrome to be conceptualized as a secondary network disorder that results from breakdown of normal network behavior, opening up the possibility of new therapeutic avenues.
Dr Edouard Hirsch then talked about electrographic status epilepticus in sleep / Landau-Kleffner syndrome. He posed the question of whether treatment is treating the epilepsy or treating the seizures. The condition presents with a psychotic phase, with evolution of seizure types, sleep consolidation problems, network dysfunction, and cognitive dysfunction. Treatment is with benzodiazepines, steroids, and immunoglobulins. There are multiple etiologies, and the new research direction is evaluating the emerging relationship between EEG activity, blood flow, and sleep, and what effects these disruptions may have on the glymphatic system. There is a need for an international study on pathophysiology, therapy, and etiology in this condition.
Dr Angela Vincent gave the final talk in this session on autoimmune encephalopathies. She stressed that these usually cause a loss of function in the protein affected and/or damage to cells, but that patients can improve with immunotherapies or plasma exchange, and quick and effective treatment is crucial. She also stressed that this requires quick and accurate diagnosis. Dr Vincent highlighted the fact that 10% of pediatric patients with new-onset seizures of otherwise unknown etiology may benefit from antibody screening.
Session II covered the molecular features and pathogenesis of epileptic encephalopathy. Dr Gregory Holmes questioned whether seizures or etiology play a more important role in the development of encephalopathy. He gave 3 examples of situations in which early-life seizures impact the network's ability to develop normal rhythm required for learning and memory. He also discussed how some of his animals developed adaptive strategies to be able to overcome that deficit. In addition, he gave the example of interictal spikes interrupting memory retrieval and made the point that if single spikes are able to do this, both in the hippocampus in terms of memory retrieval and the prefrontal cortex in terms of attention, what is actually happening in a condition like electrical status epilepticus in sleep?
Another example Dr Holmes provided was that of Dravet syndrome, in which it is possible to separate the effects of seizures from the effects of the sodium channel etiology, suggesting there may be conditions in which fixing the seizures may not be sufficient to fix the cognitive issues. Therefore, other approaches are needed. The cause of epileptic encephalopathy may be a very major determinant in cognitive outcomes and the modifiability of cognitive outcome.
Dr Sookyong Koh discussed neuroinflammation and the role of the microglia in the brain. She highlighted the priming effect of early-life seizures in her model. Early-life seizures can increase susceptibility to seizure-related damage later. This susceptibility can be modified by several things, including dexamethasone, minocycline, and the enriched environment. She concluded her discussion by hypothesizing about whether drug-resistant epilepsies actually evolve into immunemediated disease.
Dr Tallie Baram closed the session by laying the framework for thinking about how neurobiology underlies different epileptic encephalopathies. Her tenet was that being able to classify things into mechanistic clusters could enable better approaches to precision medicine, and she shared a number of examples of dysfunction that could arise from something like a single-gene mutation, but that also could come from injury. Other environmental experiences also might modify neuronal function in several ways, leading to dysfunction that actually causes neuronal death, affecting circuit behavior and reorganization of normal circuits that then lead to epileptic encephalopathy and nonneural effects such as inflammation, along with deficits in synaptic regulation and metabolic homeostasis. She concluded her discussion by highlighting nodes for intervention, including epigenetics, metabolism, and inflammation. Understanding the relative contribution of these different factors for an individual patient might be important to tailoring appropriate individual therapy.
Session III covered therapeutic targets and translational opportunities related to epileptic encephalopathy. Dr Shlomo Shinnar talked about the current best treatment options and the need for randomized controlled trials in these syndromes. He discussed the new International League Against Epilepsy recommendations for infantile seizures, including adrenocorticotropic hormone, oral corticosteroids, vigabatrin (for tuberous sclerosis complex), and dietary treatment, which is not firstline treatment. He mentioned that surgery can lead to freedom from seizures in appropriate cases as well. He also stressed that future research is needed to understand the optimal treatment of infantile spasms and the effects of treatments and seizures on long-term outcomes.
In terms of Lennox-Gastaut syndrome, Dr Shinnar discussed the success of the ketogenic diet compared with more traditional therapies, and mentioned surgery can be effective as well; however, there is no consensus on what the best surgical approach is. In electrical status epilepticus in sleep, results from nonrandomized series revealed that surgery followed by steroids appeared to be the more effective approaches. In the autoimmune encephalopathies, there are no consensus guidelines, but the immunotherapies appear to be the best approach in these types of disorders. He stressed that early effective treatment leads to better outcomes and there is a great need for randomized controlled trials and new agents.
Next, Dr Mike Wong discussed targeting the mTOR pathway for epileptic encephalopathies. He focused on the idea that hyperactivation of the mTOR pathway probably plays a key role in epileptogenesis in these disorders. In tuberous sclerosis, the incidence of infantile spasms and epilepsy is very high. As such, there is a real possibility of identifying people prior to the onset of seizures or spasms. In fact, some patients can be diagnosed in utero as a result of cardiac rhabdomyomas and other abnormalities, and so this set of patients really presents an opportunity to think about prevention. Once the genetic basis is known and there is a clear biomarker for individuals who are at high risk for developing epilepsy, this is a population in which prevention could be considered.
The highlight of Dr Wong's talk was the fact that there is convergence of available mTOR inhibitors, and these can also serve as parent compounds for medicinal chemistry approaches. Also, multiple animal models of tuberous sclerosis have been useful for epilepsy in the past. There are readouts of mTOR activity, at least in the models, and there are clear targets for intervention in terms of the downstream partners in the mTOR signaling pathway. A randomized controlled trial is currently recruiting for drug-resistant epilepsy patients using an mTOR inhibitor and in the future, it is hoped that prevention studies will be coming out of this area.
Dr Amy Brooks-Kayal reviewed the status of cannabinoids for epilepsy. She highlighted that the endocannabinoid system makes sense in terms of thinking through a new way to regulate neuronal excitability. There is preclinical support for cannabinoids in animal models of epilepsy, but given the state of the clinical evidence no reliable conclusions can be drawn. Researchers are in the process of developing evidence for this category of intervention. There are ongoing randomized controlled trials for Dravet and Lennox-Gastaut syndrome, and Dr Brooks-Kayal alluded to central nervous system toxicities and mentioned that these have been observed in multiple animal models and in patient populations where therapeutic cannabinoids are being used. She emphasized that those need to be balanced with the potential benefit that might accrue from the use of cannabinoids in epilepsy. She also addressed the regulatory situation, and commented that the current state of "legalized" and "not legalized" and state-by-state regulation is probably not optimal. Lastly, Dr Jack Parent talked about engineering of stem cells. He discussed engineering patientderived stem cells for drug discovery, for understanding mechanism, and also for the idea of ultimately looking to these cells for transplantation in the brain as a potential therapy.
SESSION IV: Future Directions Panel Discussion
DR FUREMAN: So, as a whole, we had tremendous talks today. I think that they all raised very compelling questions and research questions certainly, and I want to thank the course directors for putting together such a terrific session, and also for all the speakers, and I apologize for not being able to do all of you justice.
So I think for now we will turn it over to our panel to hear some reactions from them and I will introduce them very briefly because I think they are all well-known to you. To my left is Dr Jackie French, who is professor of neurology at NYU, and who is the leader of the epilepsy study consortium. Jackie brings a great deal of expertise in clinical trials in epilepsy. Next to her is Anna Poduri, who directs the epilepsy genetics program at Boston Children's Hospital, and obviously her expertise is in the genetics of epileptic encephalopathies. Next to Ann is Aristea Galanopoulou, who is professor of neurology and neuroscience at Albert Einstein College of Medicine, and she brings expertise in both the age-and sex-specific models of epileptic encephalopathies, and expertise in the basic mechanisms of these disorders.
And I should mention that both Aristea and Jackie are also part of an ILAE AES task force on translational research, and the goal there, and they can talk about this if they'd like, is to improve the standardization of translational research studies, improve the ability to compare data across studies perhaps using common data elements, and as a whole really, accelerate our progress toward therapy development for humans.
DR FRENCH: You are a member, too. DR FUREMAN: I'm also a member. So, next to Aristea is Dr Lionel Carmant, who comes to us from the University of Montreal. I'm sorry my French is no good, but he is professor of neuroscience and pediatrics there, and he has interests in neuroprotection and targeted treatment strategies. Eric Kossoff is next to Lionel and he comes to us from Johns Hopkins University, where he is professor of neurology and pediatrics. He has expertise in the ketogenic diet and other non-medicinerelated therapies for epilepsy. And finally, our esteemed colleague Dr Jack Pellock, who is professor of neurology, pediatrics, pharmacy, and pharmaceutics at Virginia Commonwealth University, and Jack's expertise is too long to list, but I wanted to mention that today he has a particular interest in talking about seizures and clusters and status epilepticus, which are at high risk in these disorders as well.
So, I am going to ask our panelists each to spend just 2 or 3 minutes giving us their highlights from the day, and then we will be opening it up to questions from the audience, and I have got a few targeted questions if we have no takers in the audience. So, Jackie will you start it off.
DR FRENCH: As some of you know, I am an adult epileptologist at a pediatric epilepsy meeting, but it has been really fabulous to be here because of what I have been asked to do over the last year, and I think that this is very relevant to all of you. So, as you heard from Brandy, I am the head of The Epilepsy Study Consortium, which is a nonprofit that tries to help Pharma do the most efficient, expedient, and correct trials that they possibly can, and when I started doing this, it was all about adult trials and all of you were very frustrated because it was all about adult trials, and now we have 22 drugs for adults and the pharmaceutical companies that were making those drugs are saying, no more, no more business as usual. We are not interested in that audience. It's overserved, and big Pharma has kind of retreated.
At the same time, small Pharma, and I'm talking really small Pharma, suddenly has jumped up and said look, there are all of these orphan indications in epilepsy, these epileptic encephalopathies. It is the perfect storm. If you are a small company and you are interested in developing a new therapy. The perfect storm is that it's a very unique population often with unique pathophysiology with a very energized community that will help you find patients, and when you develop a drug in this area, you will get an orphan indication, and an orphan indication to them, to a small company, is like gold money in the bank because they get to do fewer trials. They get to do more targeted trials. They get exclusivity beyond what they would normally get. They get some relaxation of the rules from the FDA and then, you know, if they have a very small sales force, which they often do, or maybe they're going to now take that product.
Let's say they've taken through proof of concept and move it off to a bigger company at the end of that and they are all waiting to like grab it, but if you are going to go ahead, your small sales force can take care of this small audience. So what has happened in the last year is a complete flip where there is no development in adult epilepsy anymore and there is enormous development in pediatric epilepsy. So everybody should be really excited and particularly for orphan diseases and particularly for epileptic encephalopathies, and what these companies are coming to me for is to say, OK, I've got this hammer and this is this unique mechanism, now where do you think the nail should be? We have got all of these different pediatric epilepsy syndromes. Should we do Lennox-Gastaut, should we do infantile spasms, yes, yes. Heaven forbid, but, you know, they've come with that question too, and so all of you in the community should know that this is happening and should know that you have an opportunity, you know, if you are a particular expert in the pathophysiology of any of those or the clinical characteristics of any of those, to really have an input to these companies.
I will say that the Epilepsy Foundation is having a pipeline conference in February where a lot of these companies will be there to sort of present what they have so far and you should, you know, pay attention and have your input on what should this hammer be used for, and we also have to think about the best way to do trials in these orphan indications the most efficiently, because we cannot waste a single patient when the communities are so small, and I will stop there.
DR ANNA PODURI: I will join Brandy and Jackie in thanking all of the speakers for really wonderful and exciting talks. I think what I took away from the morning especially is a reflection of how different things are clinically now than they were when I was a resident. If we saw a child with infantile spasms and there was asymmetry, you would rush to imaging; if not, you wouldn't get imaging right away, and then if you didn't find anything with imaging or the metabolic screens, you didn't have a cause and you tried empiric therapy.
In terms of our diagnostics now, our imaging is much better. We now think of everybody with an epileptic encephalopathy as having a cause and it's our fault if we can't find it, but we do push harder and harder for metabolic and genetic etiologies as well as imaging, but I think what we are struck with in the remainder of the talks is how our therapies have not yet caught up with that, and how we are still using the same empiric therapies without a lot of evidence.
So the theme that I wanted to develop a little bit is how and when can we move on to more precise trials, and I will focus on the genetic epilepsies because that is my interest, but I think that it applies to all of the entities that we have talked about. I think there are a lot of opportunities that were presented and I think a lot of challenges in terms of implementing them, and so one of the huge advances in genomics and medicine has been the advent of sequencing, fast sequencing, targeted panel sequencing for a given disorder like epilepsy, broad sequencing, whole exome sequencing, but getting it to the clinic, getting it to our offices has been cumbersome.
So we've dealt with it at home by establishing an epilepsy genetics and neurogenetics group by liaising with our genetics colleagues but, in particular, genetic counselors who are trained in doing this, so at minute 29 of a 30-minute visit, you can't start genetic counseling consent, but a counselor can do that in a separate venue, and so we've really been partnering with our colleagues to be able to really increase our diagnostic yield. So it's fine to say that in the Epi4 k consortium we can crack about 20% of our otherwise unexplained infantile spasms and Lennox-Gastaut, but we are only sending maybe a handful of exomes in our clinics because of various hurdles that we have yet to overcome.
So I think the way we can overcome that together is to really individually each push for the testing, reach out to our colleagues who can do this. If we don't have time to do the testing ourselves, find people who have the time to do it. The reason for which is I think all of these technologies are going to lead to therapies and the type of trials that we are talking about will happen, but if in 10 years we have targeted therapy for TSC, targeted therapy for specific gene disorders, targeted therapy for FCD caused by mTOR mutations, and we don't know who the patients are to treat, we won't be able to get very far in terms of our impact.
So I think among us as clinicians, increasing our ability to diagnose these patients is huge. We have to partner with our research colleagues and I find myself on both sides of the street. So our patients where we can't do exome sequencing, for example, who are enrolling in research studies, patients who get clinical exome sequencing, the rare ones where we don't find a cause, we are partnering with an INDSN cure to do an edit of reanalysis of their data. Someone mentioned this morning, you just get these variants of uncertain significance. Well, if we put all of our variants of uncertain significance together over the next few years through the Epilepsy Genetics Initiative, then maybe we can actually figure them out when we have several cases instead of a lot of anecdotes, and then I think the main thing that we are missing now is a really clinically relevant, relatively medium-to high-throughput weight to functionally characterize our variants.
So if we do exome sequencing on a hundred patients, we find putative causes in 20 of them, and 5 of them look like they're potassium channel gene mutations. The indication is to say, well they are drugs for potassium gene mutations, let's go out and get Potiga, and the problem is we don't really know if they're causing a gain of function or a loss of function. Are they causing too much potassium flow or too little potassium flow? So we really have to work with our bench colleagues who have systems set up in several different systems.
So we have heard about the traditional cell culture systems, rodent systems, a little bit about zebrafish. We are hearing about these very exciting and cool IPSC systems that are patient-specific and can be reprogrammed into all sorts of neurons that are relevant. We should bring our questions from the clinic. You know, how do we model this particular patient's potassium channel mutation in the best system? How do we model the symptoms that we want to target with therapy? How do we model epilepsy versus the comorbidities, and develop platforms where we can do this in a reasonably high-throughput fashion?
I will give you one quick example, which is based on the glutamate receptor story we heard about earlier. Tyler Pearson reported a GRIN2A maintenance that was characterized by Steve Trendelis [phonetic] and it was a gain of function mutation that responded to memantine. No sooner had that come out than one of our colleagues came and said, "hey, I've got a patient with a GRIN2A mutation, the parents want memantine, there have been no clinical trials, no published report." Our hospital said, "hey, there's an FDA-approved drug and there is a published report, you don't have to do an IND." We said, "that's great, but we don't know if it's gain or loss of function."
So it happened that I had run into Steve Trendelis at a conference about 2 weeks prior who very, very quickly, in the matter of a few weeks, characterized the mutation, showed it was responsive to memantine. And then we said we have no idea how to dose memantine in babies, and we convened a group of experts and said we do need a clinical trial before we get that going, so we used compassionate use group approach to what we would think was reasonable dosing, so I don't think it's a great idea because it doesn't allow participation in a clinical trial, but since there wasn't one we did an ad hoc approach, but I think we really need to move toward building platforms and working together, putting our cases together here and there at all of our lists together and achieving something in the next 5 to 10 years. DR ARISTEA GALANOPOULOU: Thank you, Brandy, and I would also like to thank all of the speakers. As Brandy mentioned, Brandy, Jackie, a few of us are actually part of a consortium of the translational taskforce of the ILAE, and in Italy what we were planning to do is we were trying to improve the infrastructure to optimize the translation of the findings that we see in animal models into clinically relevant discoveries. There was a lot of discussion a few years back about what are the weaknesses of the animal models and what do we need to do to improve that, and earlier this year we had to deal with a completely different issue. Many of you may have heard the whole story about the-section, but just because of the problems with the animal models there was a movement in Europe to basically stop animal experimentation for biomedical research, and that was actually an opportunity for us to realize we shouldn't be as critical as to figure out the weaknesses of the models, and especially in conferences like the one that we are attending today, we should start pondering how grateful we should be that all of the animal studies have offered so much insight into mechanisms, new treatments, and into the future of biomedical research just because we are using animal models and specifically for that, if we go historically through the animal experimentation, we can see that a few decades back there was a notion that neonatal pups do not have seizures, you cannot induce seizures or epilepsy in neonatal pups, and right now we had a few models of syndrome-specific and agespecific epilepsies in epileptic encephalopathies.
We heard Mike Wong talking about rapamycin, a drug that was validated in an animal model of tuberous sclerosis, and now it is back into the clinical trials and going back into the models of infantile spasm, which have emerged, several of them, over the last 10 years we have a couple of drugs that are FDA-designated orphan drugs for infantile spasms because of work that was done in animal models and there is an intensive effort to develop new drugs specifically for epilepsy syndromes of infantile ages or very young ages, which all would be inconceivable decades ago, and for us we do a lot of work in developmental neuroscience, developmental epilepsy, we start realizing how different each day of development it is for the animal and how different very young animals and humans are actually compared to the adults, and the old idea that we have to try in young kids drugs that were characterized in adults is an issue that we have to daily reconsider.
Most importantly, now that we start developing in animal models new candidate therapy, stage-specific, age-specific, sex-specific, the main question for clinicians like Jackie would be what is the best trial that we can bring in an infantile epileptic encephalopathy, or a childhood encephalopathy, which so far everybody hesitates to do just because of all of the, you know, the cautions and concerns about what if something goes wrong, what is the safety profile, and as we know most of the phase 1 trials are done in adults, are these good enough for pediatric development? I think this is a very critical question that the clinical trialists have to start addressing in the future.
The other points that I want to make are more in terms of mentality and what animal models and also the genetic studies and many of the clinical studies have shown us is that yes, there is a lot of diversity. We are looking toward precision medicine, but we have pathways like the mTOR pathway that Mike addressed and Jack Parent also touched upon, but are not specific for one type of genetic disease, we find them in other diseases, so we have specific pathologies for certain diseases and syndromes, but we also have areas of convergence, and as we go ahead I think it is very important to avoid polarization.
We shouldn't be very dogmatic about genetic models or-of the future or nongenetics, it's somewhere in between. We have to keep it balanced, we have to work as a team or it is something that many agencies like NINDS are trying to implement with-without walls consortia like the ones that Anne mentioned or the Cure Infantile Spasms initiative that brought together clinical investigators to try and find better therapies, the future comes out of this. We have to work as a team. We have to work in a rational way, avoiding polarization, and try to take advantage of everything that we had. Whenever we are critical, it is like when we are critical for our kids. We want the best out of them, it is not that we don't believe in them, and it is very important to keep emphasizing that. Otherwise there is not going to be any future.
DR LIONEL CARMANT: I want to thank the organizers for a fantastic day. My take-home messages for today are first of all, I think that the diseases we talked about today are clearly diseases of the synapse, and to use a term that a lot of people in the --and autism field use, I think those are like epileptic synapsopathies, and that would explain why so many disorders, when they occur at a specific time, lead to a similar phenotype, whether they are immune, genetic, or lesional.
I think one other question that wasn't really answered today that we need to think about is why it is in some cases reversible and in others it is irreversible? That is one of the things we need to do, and to do this, I think we need to better study the patients with the cryptogenic forms of epilepsy. A lot of my genetics colleagues don't want to spend too much money into these patients because the yield of doing old genome in these patients is not as high as the ones with ID, but I think we need to study them better to understand why in these patients can the disease be reversed, because I think that even though we say there are medically refractory patients because they don't respond to conventional treatment, I think it is because the disease does not involve ion channels, so they won't respond to ion channel blockers, while they seem to respond very well to either vigabatrin-ACTH up to 90% do respond, so if we can treat them early enough we can improve the outcome of a lot of these patients.
Another interesting thing to-like you mentioned would be to use presymptomatic treatments, and we mentioned that TS would be a good cause, encephalopathy would be another condition that presymptomatic treatment can be thought of in these populations. Our group sent out a small paper of 3 patients with cardiac malformations, NTS, pretreated because of the cardiac malformations with rapamycin everolimus. Unfortunately, one of the 3 patients did develop infantile spasms, but we are still following him up to see if it will develop or not the comorbidities associated with infantile spasms.
We did a Canadian trial for infantile spasms looking at neuroprotection because as I said I think the spasms themselves can be-well-treated. The question is can we prevent the consequences of spasms. The drug we used was fludarabine, a drug I had worked with when I was in Greg Holmes's lab and a neuroprotective drug preventing neuronal death, and we had some encouraging results at 2-year follow up. But at 5 years there doesn't seem to be a difference, because those that recover seem to completely recover over a prolonged period of time, but now that we better understand the disease rather than preventing neuronal death I think what we need to prevent is synaptic dysfunction and we'll discuss the mTOR target. I think that is a great target because mTOR seems to be a general of whatever is happening at the synapse trafficking, and someone from our group-using an autism model where he mutated the initiating factor for epsilon [phonetic] to cause autism in a mouse model showed that he was able to reverse the phenotype with 5 days of treatment even in adult mice, so I think these things are probably reversible, we just need to find the proper target.
My last point would be maybe that we discussed as well the role of neuropsychology testing in these patients. Just a word of advice, it is very money-consuming, we tried to do Baileys at initial presentation in our Canadian study. I don't think at time zero it is very predictive. The best thing would be to do a Vineland to get their presymptomatic status, because once they are affected by the spasms, even if you see them before treatment, some of them regress so severely they stop being able to do anything and they completely recover with IQs down the road above 120 in some of our pup patients, so recovery does happen, we just need to identify who and how to better help them out I think.
DR ERIC KOSSOFF: Again, thank you very much to all of the organizers, this has been a really great day with lots of excellent lectures and also topics that really were all extremely interesting all throughout the day. As a researcher of the ketogenic diet, it is also very nice to be part of this discussion and part of this panel.
For epileptic encephalopathies especially, the theme we have been hearing today over and over is that conventional AEDs don't work; that keeps coming up lecture after lecture. And we heard about CBD, rapamycin, and we heard about stem cells, steroids, and other therapies, so the ketogenic diet certainly fits into one of those categories as a nonconventional therapy, non-anticonvulsant drug therapy. Although some of these therapies have short experience, the ketogenic diet has 94 years of experience, so we know a lot about it and it's a natural thing to look at for these conditions. As I heard these talks today, there were really kind of 3 major points that I took out of it that really express how the ketogenic diet should be looked at for these epileptic encephalopathy. Number 1, there is a growing recognition that infants can do very well with the ketogenic diet; for many years it was almost the opposite mindset that ketogenic diet should be used in infants due to growth and other issues and side effects, and now we have almost done a 180 where probably the largest, certainly at Hopkins, the fastest-growing population of patients we are seeing is infants. With all of the ketogenic formulas on the market now, compliance is assured, and children, very young children can do extremely well with these formulas.
There was just a paper Brandy pointed out to me that I had just seen literally 2 weeks ago that came out from Vienna from Dr Dressler's group, where they looked at children in their large cohort under a year-and-a-half of age versus over a year-and-a-half of age, and it was twice as many that were seizure-free in the under 1-and-a-half year of age group, which was pretty dramatic. There were hints of this in other studies before that infants do very well but nothing really this specific pointing out how well infants can do. So I think certainly as these epileptic encephalopathies primarily affect very young children, the ketogenic diet makes some sense in that group.
Second, as we heard in the morning about all of these syndromes, infantile spasms, Lennox-Gastaut syndrome, ESES, and then even this afternoon we heard a lot about Dravet syndrome and tuberous sclerosis, if you read the 2009 Epilepsia ketogenic diet consensus paper, the first table, lists indications for the diet that was it. It pretty much matches all of these conditions in terms of what we known with very well-done studies, large studies saying that the ketogenic diet may be very, very effective for these conditions, and so something seems to be in common here, that these conditions that you are talking about here today seem to be those that respond very well to the ketogenic diet, suggesting maybe that the mechanisms may be very similar.
The third, which I thought was really great, was when Dr Baram was talking about targeting metabolism. As many of you may know in the ketogenic diet world, the basic scientists outnumber us 2:1 for clinical science, and there is a movement among the basic scientists that we should stop calling it the ketogenic diet, that we should be calling it MBT-or metabolism-based therapy. There are a bunch of these, not just ketogenic diets, but 2DG, triheptinone, ketone esters, that seem to be working. Adenosine is another one recently that targets metabolism, and so there may be some commonalities in terms of these epileptic encephalopathies maybe being very responsive to therapies that target metabolism.
Maybe it's because they are anti-inflammatory. We heard pros and cons about that earlier, but that keeps coming up as well in the ketogenic diet community, that there may be some anti-inflammatory benefits of ketogenic diet therapy, cytokines, and other markers. A condition called Fire syndrome, which may be potentially inflammatory, seems to respond very well, so there are some interesting parallels that would make the ketogenic diet a very viable target as a therapy that should be looked at due to these metabolism-based therapies. And I think future direction, certainly, besides looking at these for all of these conditions, larger studies, certainly with long-term and as we heard neuropsych testing, would be very useful to know what effects does the diet have not just on their seizures but also on cognition and long-term outcomes.
But something that is certainly not unique to any of our therapies is that the diet is often used with anticonvulsant therapies or other medicines, and as we were looking at these we heard about the ICISS study that perhaps maybe the diet should be used in a combination study for infantile spasms or Lennox-Gastaut syndrome and try to maybe target that as a good combination versus a bad combination. One that has come up recently -the thought process that could you do ketogenic diet and steroids together. For many years that was said to be a no-no, you couldn't do the two together, that they negate each other. Yet a paper a few months ago out of the group from Paris said actually in 42 patients with epileptic encephalopathies they actually worked very well together. So potentially ketogenic diet and steroids or ketogenic and vigabatrin. These combinations may be very helpful and are certainly worth looking at. DR JACK PELLOCK: Thank you. Number 1, I agree with all of you. Bernie did a great job, Tallie, Shlomo, Brandy, all of the speakers. I'm the old guy and the last guy in the line here, so what I heard today is number 1, these are rare disorders. But why are we all here? Early and often is when they are in our offices, early and often is when we get the phone calls. Early and often is when we throw up our hands and say "I've done the best but it's not good enough."
So where do we turn? Well, let's look at these rare disorders. Do we treat them with anecdote or evidence? The best evidence we have perhaps isn't good enough, so we need more. I certainly, certainly fully endorse the studies in infantile epilepsies, and within those studies we need true trials, good endpoints, the illness has to be defined perfectly. Unfortunately, when you only have 30 people in a trial and there are 60 etiologies, it is a little difficult sometimes to compare who did what or how they did, but you know we can still get information if we share our experiences within protocols.
Other diseases have done this, we have been a little bit slow, not a little bit, we have been a lot slow in epilepsy, and these disorders are crying out for that, so when we talk about the pediatric groups coming together, this is the way we have to do, but then we have to develop the right kind of protocols, the shared protocols, and for those of us then practicing, I would say, you know, you want to take that new idea out there, but the first thing is do no harm. Now we heard a couple of things today both from the animals, but let's start with the animals. Where what we thought were good therapies later, in fact, earlier on, oops, and we certainly don't want to go there, so we need that evidence before we do go there, and Brandy, you are going to fund all these, right?
DR PELLOCK: We do need better funding. The Rend is a great idea, but the fact is, a lot of parent information, we need the medical information to go along with it to make sure that we have the right populations within them. If you think about the whole day, I went back in my mind to the Institute of Medicine report a few years ago. Epilepsy is a spectrum disorder. We talked about the encephalopathy, the seizures, the seizures, and the encephalopathy-that is what it is all about. So, besides the medicines and the devices and the diets, you talked about the environment of the rat. Was it a good environment or not, and did they do well or not?
Kids go to school, they have families, besides the treatments that we think of as treatments, have we supported those families? Well, pretty hard. In many, it is very, very difficult, but I think we need to consider those avenues of treatment and I am not big on holistic medicine, although what I am saying is, you have to treat the whole patient and the whole family, and then they can take the best medicines or the best treatments we can give them and optimize them. Prevention of the encephalopathy, yes that is what we are all about. Prevention of the seizures in some people, there is nobody here who hasn't cleared up a kid's seizures and watch them brighten up. We have all done that, so it is hand-in-hand. Let's do them both together and let's see if there is a best treatment for the seizures that, in fact, helps the encephalopathy the best, or do we need alternative or additional medications or perhaps the same medicine that we are not thinking of or don't have available yet.
When I say medicine, it is any treatment, I don't care what it is, that we need to do that and we need to bring them in to the kids. We have a group together trying to do extrapolation partial seizures down to children where we don't have to go through trial after trial after trial and duplicate them. It has been done in other areas. We are working with FDA industry, everybody and it is moving forward, hopefully, it will get there. And, just one last comment. Epilepsy kills. Epilepsy kills. This group at a high risk for SUDEP and other disasters. We must be aware of it. We have to treat it effectively, timely. I am not even going to talk about status and those things yet, but we have to be there and get the right therapies and don't give them the wrong therapies. Take those away. Thank you.
DR FUREMAN: Thank you, Dr Pellock. Nobody could have said that better. Thank you. So I just want to expand on 2 things that our panelist said. Number 1, the idea of infrastructure and platforms to come together to develop research, so the PERC is one example, this is an infrastructure that is up and running and collecting data and producing important work, and there is also an opportunity through the NINDS NeuroNEXT Network for phase 2 clinical studies and biomarker studies. This is an existing clinical network with a data coordinating center, bunches of statisticians who are just waiting to help you design your study and established clinical sites across the country so that investigators with strong ideas and perhaps some sites of their own can bring them to this network and get therapies tested quickly in phase 2 settings. So, I wanted to make that point.
The other is the EGI Initiative that Ann mentioned, so this is the epilepsy genetics initiative that is funded in large part by CURE, but it is done in collaboration with the NINDS Center Without Walls on Human Genetics of Epilepsy, and the idea is that for all of these clinical exomes that are being performed out there in the community, there will now be a repository to submit those clinical exomes so that they can be useful to research. This saves us money, this brings the whole community in to the genetic discovery process, but it also, I think, returns value to the patient and the family because that clinical exome now is going to be reanalyzed on a continual basis, so that when new pathogenic variants are identified, that information can come back to the family, and that very unsatisfying initial report that you got can actually turn into something that might be useful in terms of decision making.
So I just wanted to expand on those 2 points and the excellent points raised by our panel, but I also want to open it up to questions from the audience. You have been very lively and engaged throughout the day and I know it is the end of the day, but I am sure there are still some really persistent questions out there. So, please come to the microphones and as you are doing that, I think I will start off with one, perhaps for Dr Kossoff. Any downside that you can think of to the idea of combination therapy between diet and other approach.
DR KOSSOFF: Yeah, it's a good question. The question was about sort of combination therapies, and I think there always is the worry in terms of side effects being potentially additive. We do know the ketogenic diet can sometimes cause some anorexia and weight loss and some of the anticonvulsants can do that as well, and in a growing child, especially where you are worried about height, weight, brain development, that would have to be very carefully monitored as well. So, I think knowing those, especially too, there is high risk of infection with perhaps with steroids, too, and there is some potential concern with the diet. You would have to watch for that as well.
DR FUREMAN: So it sounds like some very good questions for trials.
DR KOSSOFF: Things we would have to be aware of, sure. MS FRENCH: I just want to make one point that just occurred to me as I was listening to everybody and that is, is it true that the best therapies, the ones that we have the most faith in, are the ones that cannot be subjected to a randomized controlled trial, and once they are subjected to a randomized controlled trial, maybe they lose some of their luster? I think we have to keep that in mind as we get excited about therapies.
DR FUREMAN: Good point. Dr Hirsch, I saw you have a question.
DR HIRSCH: I have a question to Jackie and to Jack. Many years ago there was a gut in drugs whereas-antagonist and this drug disappeared and we know from this drug, it was acting under network or hypothesis one was very effective on-very poor on limbic series and when you are thinking about these drugs who has had-it could be a good drug for very rare disease, encephalopathy like absence or-REM sleep because-effect on sleep increasing REM sleep, so could you tell me, if you know, why this drug just disappeared, because there was no money at this time? Can it come back today? DR FRENCH: Well, I think this is a really important and interesting point, that it may be that, I am going to talk about the flip that I was just mentioning before. There were drugs that I saw come into the arena of development and start in the focal adult epilepsy realm and failed there and then disappeared. In the new era, those drugs will be tried in other epilepsies first, and that may actually allow them and some of the old ones that we threw away, it may indeed be possible to bring them back and it may be appropriate to bring them back in the new era. I mean, we are talking a lot of even big pharma would never have gone near an orphan indication in the past and now they are looking for orphan indications, so it may, in fact, be interesting to rethink about those drugs and bring them back. And Jack? DR PELLOCK: Totally great. And I think frequently, it is the model. It is always the adult epilepsy. They forget about little kids with these things or these rare happenings, and if the model is partial epilepsy and they inadequately dose, infrequently it is an inadequate dose for children because it is too low as opposed to too high, or we are on 6 other medicines before we get the last. Nothing is going to look safe at this point. We need to, again, the right trial, at least for proof of concept with some sort of addition, some exclusions, what happened, what was the end point, and if we get that signal, then go further into development. I totally agree.
DR FRENCH: And one other point is that Dennis Dlugos has given some beautiful talks on how difficult it is to count seizures in children, so you are dealing with also trying to figure out the appropriate methodology for a lot of these syndromes, for what to count and when to count it.
DR PELLOCK: They are expensive. I mean, studying these kids with these rare syndromes, I mean think about the LennoxGastaut studies. Think about the drugs marketed right now with the Lennox-Gastaut indication. They basically had talked about drops and they redefined them as tonic or atonic. It's a drop or convulsive and the rest they say sort of an estimate of total seizures or something, but those are the 2 hard numbers where at least we can get toward them. Once you get into the less clinically apparent events, how long can you do continuous EEGs and do they correlate? Lots of difficulties, but still, you design it, we'll get there.
AUDIENCE: I have a comment and then a question. The comment is I feel bad for our colleagues that aren't in the room to hear all of you right now. There is a lot of wisdom, collective wisdom here. My question has to do with autism. Last year our NDC was on autism and we heard about the genetics and underlying mechanisms and risk factors that specific mutations posed. And we know that the prevalence of autism is high in children who have had epileptic encephalopathy and we have heard from several of the speakers about epilepsy, other forms of epilepsy as an outcome, we have heard about intellectual disability, but I haven't heard about autism. And what I am sitting here wondering about, is what the overlap is genetically between epileptic encephalopathy and autism? Is there some predictive validity to any of the specific mutations in terms of up to one-third of kids with epileptic developing autism, number 1; and number 2, on the ketogenic diet, Eric, is there any evidence that the diet changes the risk for autism as an outcome? DR PODURI: Just the first part. There is very much an overlapping spectrum of genes associated with epilepsy and autism, and I think some of their earlier studies, the first big series of genetic autisms and epilepsy looks at very recessive conditions and consign what is population, and so those are very, very rare and we are not seeing them all that often here now. Now that the De Novo epileptic encephalopathy genetic data are out and the De Novo autism data are out, very, very large groups of children, it is very clear that there is a lot of overlap.
We know that from our clinics and whether we have a genetic cause or not, many of the patients with epilepsy have autism and vice versa, but the genetics are absolutely bearing out and some of the genes that we really thought of for a long time as sort of fundamental epilepsy genes, SCN2A for example, is now on the list for almost every neuropsychiatric disorder-autism, schizophrenia-and so I think there is very much an overlap.
But I think going back to what we were talking about earlier, that we need to have more specificity than just the genes, so it is very, very good and very useful to say we have a convergence of symptoms around SCN2A, but then we really need to dissect more deeply and sort of say well, is it loss of function mutations causing one set of symptoms and gain of function causing another, or is it mutations in a certain compartment of the protein of SCN2A causing certain symptoms in the other and our treatment is going to depend very much on that.
Either there are some interesting examples of genes that have come up from large-studies, not a lot in epilepsy, but one of the few is the gene where a relatively common population variant, it will give you a slightly increased risk of epilepsy and the other population variant for schizophrenia. And so we have sort of taken the first step of saying yes, there is a convergence, so there absolutely is a convergence, so that makes biological sense because we are taking about neurodevelopmental disorders, but we have a lot of work to do in terms of figuring out the specificity of the changes.
DR CARMANT: One thing we can add in our study-we thought that maybe if we would early take care of the epilepsy and dysrhythmia, we might decrease the incidence of autism in our population, but we did not. We are still around 25% of the population. They were either genetic or lesional. What was interesting in that in some ways they were linked to the again Synastrax Trafficking and to our pathway, leading to the possibility that maybe it might be a 2-hit on this pathway that could explain why they did develop some autistic features; probably a genetic background plus the seizures themselves might contribute as well, but fortunately, even if we take the TSC patients, all of them responded very rapidly to vigabatrin, if arrhythmia was gone. Still, 2 of them developed autistic features, so there must be something else that we are not understanding right now.
DR KOSSOFF: So the last question is a very complicated one about what effect, perhaps, could the ketogenic diet have on autism and autistic features? It is complicated as such because most of the literature looked at Lennox-Gastaut patients who seem to have improvement in not necessarily autism, but autistic features, and when you try to tease out why is that, it becomes so complicated because is it that their seizures are getting better, are their spikes getting better as Jack mentions? If that happens and they are cleaned up, they become more alert, a lot of these patients you reduce their medicines and that may be helping their alertness and their autistic features, or is it the diet directly having that effect and it is hard to tease that out?
We are taking baby steps, very early steps mostly in the animal models. There is a study by Ruskin looking at an animal model of autism where the diet may have some benefits and so, there have been some early discussions about looking at the diet at least to start looking at autism without epilepsy to really try to separate the two, so that there are no complex interactions there. It is very tricky, though; again, what is autism? And defining it very clearly for any clinical trials can it be critical, but it is an intriguing idea that is just starting.
AUDIENCE: Thank you. So we have heard a lot about mechanism of development, long-term down the road, of changes in cognition and also seizures. There is a big emphasis in pediatrics now on concussions and traumatic brain injuries and mild TBI, and we know that that condition can produce this chronic traumatic encephalopathy. That is amazing to me, that something external, it's like cutting the tails off the mouse and expecting the mouse's offspring did not have tails. But I think it may also tell us something about the mechanism. I would just like to hear any comments on the mechanism of development down the road of posttraumatic epilepsy and posttraumatic encephalopathy.
DR FUREMAN: It is a topic we didn't specifically cover in this symposium today, but would anyone like to respond? DR GALANOPOULOU: If you are asking about animal models, there are some animal models that try to stimulate for somatic epilepsy. Most of them are done on animals because it is much more easy to standardize the conditions of the traumatic brain injury, but there are some groups that are trying that also in more immature animals, more postpubertal. If you look at the long-term outcomes of studies like-Buchanan and other groups that do the posttraumatic epilepsy, they do see normal patterns, they do see EEG patterns that do look like seizures. If I recall correctly, the incidence of electroclinical seizure patterns is still on the low side, like 10% or so, so there is some degree of epilepsy that enters from adults with somatic brain injury. It is not 100%, but it is still a model that can be used.
In the developing animals, there is a lot of debate. There are some models that exist there. An interesting case of discovering important EEG patterns that look like seizures, but it needs a little bit more of work to be standardized and optimized. There are a few issues that come up with these studies and this is actually one of the goals that we try to address in the translational task force, because in animals, we haven't come yet to the point that we have come in clinical epileptology. We haven't come yet to the point to classify seizures, interpret the EEG in the same way that we do the human EEG, so there is a lot of arbitrariness in the way that we look at-we do EEG studies, and every person can see the same EEG and they have a different interpretation.
So one of the key areas that we try to address through the translational task force is to kind of standardize that in a way that clinicians have done it with a human EEG outlooks and the clinical neurophysiology fellowships and the boards, so we try to basically improve that kind of infrastructure. So, overall, there are some models that have or are being developed, like fluid percussion or other models. There are trials of therapeutics that have been tested in these models and there has been talk about mechanisms that may be involved in posttraumatic epilepsy or posttraumatic syndrome, including mTOR pathway, neuroinflammation. And so, so this is an area that is very, very much developing, and also there is another pathway that is being investigated very strongly, the neurodegenerative pathways like the tauopathies, so there is a lot of interest in this area of research.
AUDIENCE: My comment is on the SUDEP and also then also the seizure count, and I will start off by saying I am wearing a conventional watch, but the current Apple watch has an app for seizure detection and it also has the ability of doing a pulse and also making a phone call through an iPhone if it is matched up with that, so I think we are still in that infant stage.
I am not concerned about the Apple iPhone 2, but maybe version10 or something in the future.
DR PELLOCK: All of these things are good and they are not perfect, we all know that. The question is, are we yet able to tell everybody to go get one and who should? What kind of seizure do they have, at what age, at what time do they occur? I am not speaking against it, but I am not endorsing it yet. I think we need better application, but what we can do, and this is a, thank you for asking that because I get to make my point-seizure emergencies. Ten years ago, 15 years ago, we had this big movement. Everybody had to have a seizure plan, an emergency plan. It went by the wayside. And what we have now is, everybody is sort of doing their own thing, a little bit of this and a little bit of that, and some people don't even mention it.
If there is ever a group that needed to have a plan for prolonged seizures or clusters of seizures, this is it, so however you want to give your benzodiazepine, whichever method you like, whatever the amount, we only have 1 FDA-approved one, that is fine. It is not perhaps acceptable for everybody, but please talk about it because I think keeping these people from this constant onslaught of uncontrolled seizures and having no emergency plan is about the worst thing we could do.
DR PODURI: Can I add to that quickly? Children with asthma at our hospital are required to have an asthma action plan. You cannot leave the office without that. There is really no reason we shouldn't do the same.
DR PELLOCK: It is in our, it is one of the list that you are supposed to discuss, but I am afraid we get so inundated with the school forms and other, all of which are important, that we sometimes forget this part. AUDIENCE: So, over the last 20 years I have been researching the psychosocial aspect of epilepsy in children. We developed a patient-reported outcomes and used it and, for example, this year we reported that the most important factor for quality of life in childhood are social support mediated through mental health, yet there is somehow a hiatus in the relationship between us and some more biological research of epilepsy. But in a way, we all know the risks of biological associated to everything which happens in our head. I always say it's all in your head, and so some people are surprised that a group of mice are doing in an isolated mice between but we know it from people, from patients from children with epilepsy, so I think a closer collaboration and more thinking together may actually improve those things we are doing now and intervention started, to try to increase this participation and social collection and see whether that has any effect as measured by patient-reported outcome.
MR KURT SAMSON: There are many personal testaments about cannabidiol and the other being very effective for epilepsy. Why is there a gridlock between the DEA and the FDA? How do we evaluate for autism in epileptic encephalopathy?.
DR FURENAN: None of us here can explain the gridlock. DR CARMANT: We have got a pretty good response from using the screening questionnaires that are available for general kids and checked follow-up as far as diagnosis is concerned, and it correlated very well in that population with the formal evaluation. The problem is those with intellectual disabilities, a number of patients could not be evaluated because of their severe intellectual disability, and this is where the border region is difficult between whether they are autistic or not. But in general, I think the diagnosis is pretty adequate. As far as the treatment is concerned, that is what we are looking for, an appropriate treatment, and for the ADHD, well, I think it is always good to treat these patients; there is no real contraindication to treat them.
DR PELLOCK: Just ICD-9 had an epilepsy-related disorder, they kind of had an expanded code so they got us into the comorbidities. ICD-10, depending how many decimal points you want to go out, will get you other things, and if people will read all of our stuff, but I think emphasis on the comorbidities that go along with epilepsy is a very important part of what we need to do and because it is being somewhat recognized as you have just said, we will get there and be able to see how many are really there. Thanks. DR BERNARD MARIA: First of all, some of the keys of success in a symposium like this daylong is starting on time and ending ahead of schedule, so I am pleased that we can report we can do that. I am very grateful to our panelists and I would like you to give them a really good hand. Thank you for your continuing support of NDC. DR PAUL ROSSMAN: Could I take a moment of everybody's time? I wasn't scheduled to be on the program and I hadn't planned to talk. My name is Paul Rossman, I am a child neurologist from Boston. I have had the honor; I guess I have lived long enough to attend 42 of the 44 child neurology annual meetings. The 2 that I missed, one my daughter got married and I was invited, the other was a snowstorm in Boston and we couldn't get out.
I met Bernie Maria many years ago when he came to Boston inquiring about a job. I hadn't known him. He was from Canada and I was from Canada and he just exuded an intelligence and enthusiasm and an energy that was absolutely infectious. I have seen him over the years and have attended just about every one of these meetings and during the meetings, Bernie is very gracious about thanking the co-chairs of the meeting as he did with Shlomo and Tallie today and thanking everyone else, but one of my colleagues who flew in with me from Boston yesterday, when I asked him if he was going to be attending the meeting, he said, "Of course I am." It is going to be the best part of the meeting and I personally want to thank Bernie very, very much for the tremendous job he has done during these 15 years. We are really in his debt and I think he holds a great round of applause. Thank you, Bernie Maria.
